: The AMEDEO Literature Guide

Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Leukemia

Free Subscription

Articles published in Leukemia
Retrieve available abstracts of 592 articles:
HTML format

Single Articles

October 2026

FIORICA G, Wehmeyer G, Yee CI, Segovia D, et al
Concordance between bone marrow and blood measurable residual disease after first-line novel agent treatment for chronic lymphocytic leukemia: a systematic review and meta-analysis.
Leukemia. 2026 Oct 22. doi: 10.1038/s41375-026-03178.
PubMed

VISENTIN A, Gaffo E, Furstenau M, Rogers KA, et al
Correction: Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study.
Leukemia. 2026 Oct 16. doi: 10.1038/s41375-026-03167.
PubMed

VAZQUEZ R, Sajot M, Nasrallah J, Birsen R, et al
Inhibition of PHB2/PINK1-mediated mitophagy potentiates venetoclax activity in acute myeloid leukemia.
Leukemia. 2026 Oct 13. doi: 10.1038/s41375-026-03160.
PubMed Abstract available

PARK J, Kim SH, Park J, Park H, et al
Correction: BCR::ABL1 tyrosine kinase inhibitors induce ribosome collisions to activate ZAK-dependent ribotoxic stress and apoptosis in chronic myeloid leukemia.
Leukemia. 2026 Oct 9. doi: 10.1038/s41375-026-03166.
PubMed

HEIN N, Poh P, Powell JA, Nunez Villacis L, et al
Novel RNA polymerase I and cyclin-dependent kinase combination therapy for the treatment of aggressive acute myeloid leukemia.
Leukemia. 2026 Oct 8. doi: 10.1038/s41375-026-03148.
PubMed Abstract available

PAIVA B, Burgos L, Gonzalez C, Ahdadi A, et al
Measurable residual disease assessment as an early end point of treatment efficacy in acute myeloid leukemia: a multinational PETHEMA study of 2623 patients treated with intensive therapy.
Leukemia. 2026 Oct 8. doi: 10.1038/s41375-026-03153.
PubMed Abstract available

ASPAS REQUENA G, Aguiar E, Brioso J, Ayala R, et al
Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registry.
Leukemia. 2026 Oct 6. doi: 10.1038/s41375-026-03154.
PubMed Abstract available

FUJITA M, Ureshino H, Kimura S
Chronic myeloid leukemia in a global context: confirmatory findings and novel discoveries from a refined Japanese Cohort.
Leukemia. 2026 Oct 6. doi: 10.1038/s41375-026-03155.
PubMed Abstract available

GANG M, Gale RP, Walter RB
Recombinant hematopoietic growth factors in acute myeloid leukemia.
Leukemia. 2026 Oct 5. doi: 10.1038/s41375-026-03158.
PubMed

U NIEMANN C, Munir T, Owen C, Follows G, et al
First-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survival.
Leukemia. 2026 Oct 2. doi: 10.1038/s41375-026-03150.
PubMed Abstract available

CHOI MY, Ghia EM, Siddiqi T, Barrientos JC, et al
Inhibition of ROR1 signaling with zilovertamab plus ibrutinib in chronic lymphocytic leukemia: safety, mechanistic insights, and an exploratory signal in del(17p) disease.
Leukemia. 2026 Oct 2. doi: 10.1038/s41375-026-03131.
PubMed Abstract available

DROBNA-SLEDZINSKA M, Buratin A, Roncaglia E, Caregari A, et al
Systematic profiling of AGO2-associated circRNAs and functional investigation reveal circN4BP2L2 as a survival-promoting regulator in T-ALL.
Leukemia. 2026;40:2223-2235.
PubMed Abstract available

KIM AS, Long T, Oldridge DA, Jennings LJ, et al
Improved inter-lab precision after CML international scale adoption: a 15-year history of BCR::ABL1 proficiency testing.
Leukemia. 2026;40:2236-2243.
PubMed Abstract available

HEIBLIG M, Gross Z, Belhabri A, Tauveron-Jalenques U, et al
Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry.
Leukemia. 2026;40:2191-2201.
PubMed Abstract available

STEINHAUSER S, Sreenivasan VKA, Baden D, Denker M, et al
Alterations in 3D-DNA architecture drive unique leukemic profiles in IDH1- and DNMT3A-mutant acute myeloid leukemia.
Leukemia. 2026 Oct 1. doi: 10.1038/s41375-026-03152.
PubMed Abstract available

September 2026

GURU MURTHY GS, Shah B, Badar T, Leonard J, et al
Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
Leukemia. 2026 Sep 14. doi: 10.1038/s41375-026-03130.
PubMed Abstract available

ZINZ R, Rohde C, Pauli C, Zhou F, et al
Functional characterization of snoRNA-derived RNA (sdRNA) expression in healthy hematopoiesis and acute myeloid leukemia.
Leukemia. 2026 Sep 4. doi: 10.1038/s41375-026-03120.
PubMed Abstract available

TALLEUR AC, Metais JY, Li Y, Schell S, et al
CD19-CAR T cells persist long-term in the cerebrospinal fluid of pediatric, adolescent and young adult patients with B-cell acute lymphoblastic leukemia.
Leukemia. 2026 Sep 3. doi: 10.1038/s41375-026-03108.
PubMed

YANG M, Lu T, He Y, Chen C, et al
KLF4/MLL3 complex axis drives NRBP2 transcription to eliminate acute myeloid leukemia cells.
Leukemia. 2026 Sep 2. doi: 10.1038/s41375-026-03117.
PubMed Abstract available

XIA C, Pradhan D, Wang W, Tang Z, et al
Blastic plasmacytoid dendritic cell neoplasm: ontogeny, immunophenotype, genetics and epigenetics, immune dysregulation, skin tropism and therapeutic implications.
Leukemia. 2026;40:1868-1878.
PubMed Abstract available

BEIRD HC, Kannan S, Liu J, Chen J, et al
Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II.
Leukemia. 2026;40:1951-1960.
PubMed Abstract available

WEI JY, Liu ZW, Lu QS, Qin YJ, et al
Linperlisib enhances MUC1-Tn CAR T cell efficacy by inhibiting EGR1/DUSP2 axis to prevent CAR T cell exhaustion.
Leukemia. 2026;40:1935-1950.
PubMed Abstract available

August 2026

YATES SJ, Terman E, Miller L, Cursio JF, et al
Association of sarcopenia with treatment tolerance in older adults with acute myeloid leukemia using artificial intelligence computed tomography-segmentation and a geriatric assessment.
Leukemia. 2026 Aug 31. doi: 10.1038/s41375-026-03099.
PubMed

BADAR T, Foran J, Jamy O, Lin C, et al
Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study.
Leukemia. 2026 Aug 31. doi: 10.1038/s41375-026-03119.
PubMed Abstract available

MOSER LM, Hutter M, Ahlmann M, Alonso-Saladrigues A, et al
Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome.
Leukemia. 2026 Aug 31. doi: 10.1038/s41375-026-03105.
PubMed Abstract available

DANEMAN MR, Meika B, Armendariz L, Tjahjono E, et al
Cheminformatic identification of small molecules targeting acute myeloid leukemia.
Leukemia. 2026 Aug 27. doi: 10.1038/s41375-026-03104.
PubMed Abstract available

CAO Z, McCannell KN, Yu S, Budinich KA, et al
PTBP1 controls oncogenic transcript processing and maintenance of acute myeloid leukemia.
Leukemia. 2026 Aug 24. doi: 10.1038/s41375-026-03098.
PubMed Abstract available

BHATIA S, Meng Q, Hageman L, Palmer SB, et al
Health status impairments in tyrosine kinase inhibitor-treated chronic myeloid leukemia patients versus blood or marrow transplant survivors and non-cancer controls.
Leukemia. 2026 Aug 21. doi: 10.1038/s41375-026-03123.
PubMed Abstract available

LI Q, Xing P, Xu J, Li J, et al
Oncogenic DHX15 mutation enhances mitochondrial metabolism and sustains leukemia stemness.
Leukemia. 2026 Aug 21. doi: 10.1038/s41375-026-03102.
PubMed Abstract available

EICHINGER A, Szmit Z, Kleinschmidt K, Abouqateb M, et al
Total body irradiation versus chemotherapy before stem cell transplantation in children aged two to four with acute lymphoblastic leukemia-an EBMT pediatric diseases working party study.
Leukemia. 2026 Aug 21. doi: 10.1038/s41375-026-03114.
PubMed

DABKOWSKA A, Janowska M, Pastorczak A, Domka K, et al
mTORC1 inhibition upregulates CD20 and enhances anti-CD20 antibody efficacy in B-cell precursor acute lymphoblastic leukemia.
Leukemia. 2026 Aug 19. doi: 10.1038/s41375-026-03093.
PubMed Abstract available

STAEHLE AM, Perner F, Staehle HF, Gellrich K, et al
A novel role for transcription factor NFE2 in redox regulation and chemotherapy resistance in acute myeloid leukemia.
Leukemia. 2026 Aug 19. doi: 10.1038/s41375-026-03095.
PubMed Abstract available

ESPARZA N, Defrene J, Bresson E, Soufflet AC, et al
Modeling KRAS mutations in KMT2A::MLLT3 acute myeloid leukemia promotes leukemic progression and transcriptional rewiring.
Leukemia. 2026 Aug 18. doi: 10.1038/s41375-026-03112.
PubMed

FUJITA M, Ureshino H
Do FLT3 and KIR3DL1 converge on a common immune surveillance axis in treatment-free remission of chronic myeloid leukemia?
Leukemia. 2026 Aug 12. doi: 10.1038/s41375-026-03113.
PubMed

ZHAO LP, Berthon C, Fenwarth L, De Botton S, et al
Real-world patterns of treatment intensity and prognostic model performance in older acute myeloid leukemia: insights from the French ALFA-PPP Cohort.
Leukemia. 2026 Aug 11. doi: 10.1038/s41375-026-03110.
PubMed

ZHANG M, Liu L, Fu S, Feng J, et al
Correction: CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.
Leukemia. 2026 Aug 10. doi: 10.1038/s41375-026-03091.
PubMed

SHAH P, Singhal A, Chang YC, Wang TH, et al
BTK inhibitors are associated with a lower risk of myeloid neoplasms and non-melanoma skin cancer compared with chemoimmunotherapy in chronic lymphocytic leukemia: a propensity score-matched analysis.
Leukemia. 2026 Aug 10. doi: 10.1038/s41375-026-03089.
PubMed

BRAVO-PEREZ C, Gurnari C, Durmaz A, Ruiz M, et al
Multilineage lymphoid clonal hematopoiesis: a cross-sectional, correlative analysis of plasma cell dyscrasias and large granular lymphocytic leukemia.
Leukemia. 2026 Aug 5. doi: 10.1038/s41375-026-03071.
PubMed Abstract available

YANG X, Peng J, Mao X, Zhang L, et al
Endoplasmic reticulum stress promotes leukemic plasmacytoid dendritic cell differentiation skewing and immune suppression in acute myeloid leukemia.
Leukemia. 2026 Aug 3. doi: 10.1038/s41375-026-03080.
PubMed Abstract available

COHEN R, Nemet S, Bezalel-Rosenberg S, Asher I, et al
Low-normal immunoglobulin suggests monoclonal B-cell lymphocytosis and constitutional CLL susceptibility: a dual-mechanism analysis.
Leukemia. 2026;40:1668-1675.
PubMed Abstract available

BICA V, Pacile AF, Boettcher M, Marano V, et al
Organelle proteomics reveals novel metabolic vulnerabilities in FLT3-ITD cells.
Leukemia. 2026;40:1657-1667.
PubMed Abstract available

WINTER L, Pawlowsky L, Muth A, Neumann AS, et al
TP53 deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretome.
Leukemia. 2026;40:1624-1635.
PubMed Abstract available

July 2026

INABA H, Varotto E, Zhou Y, Choi JK, et al
Traumatic lumbar puncture at diagnosis in children and adolescents with acute lymphoblastic leukemia.
Leukemia. 2026 Jul 31. doi: 10.1038/s41375-026-03082.
PubMed

LIAO C, Wen J, Ma X, Wang N, et al
Targeting ACSF2 overcomes Ara-C resistance in acute myeloid leukemia via the cholesterol metabolism-ERK signaling axis.
Leukemia. 2026 Jul 31. doi: 10.1038/s41375-026-03053.
PubMed Abstract available

LEHRNBECHER T, Cesaro S, Alten J, Attarbaschi A, et al
Invasive mold infection in pediatric acute lymphoblastic leukemia-a detailed analysis of the clinical trial AIEOP-BFM ALL2009.
Leukemia. 2026 Jul 29. doi: 10.1038/s41375-026-03084.
PubMed

SHEN L, Fan J, Wang N, Wang Z, et al
Adaptor-mediated rewiring of FLT3 signaling engages p38 MAPK to sustain gilteritinib resistance in acute myeloid leukemia.
Leukemia. 2026 Jul 29. doi: 10.1038/s41375-026-03079.
PubMed Abstract available

MEYER AE, Heimbruch KE, Pulakanti K, Stelloh C, et al
Cohesin haploinsufficiency and inv(16) cooperate to reinforce Fli1 gene transcriptional programs during acute myeloid leukemia initiation and maintenance.
Leukemia. 2026 Jul 27. doi: 10.1038/s41375-026-03070.
PubMed Abstract available

KUBOTA Y, Okamoto Y, Imamura T, Kada A, et al
Revisiting classical genetic subtypes reveals subtype-specific relapse patterns and MRD prognostic relevance in pediatric acute lymphoblastic leukemia.
Leukemia. 2026 Jul 27. doi: 10.1038/s41375-026-03077.
PubMed

KANTARJIAN H, Deininger M, Apperley JF, Arthur CK, et al
Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial.
Leukemia. 2026 Jul 24. doi: 10.1038/s41375-026-03009.
PubMed Abstract available

XU Q, Wang L, Liao N, Zheng M, et al
Induction-phase blood arsenic concentration and relapse risk in pediatric acute promyelocytic leukemia treated with arsenic and all-trans retinoic acid.
Leukemia. 2026 Jul 23. doi: 10.1038/s41375-026-03073.
PubMed

LIANG M, Pan Y, Saw NYL, Lu X, et al
Cumulative disruption of regulatory genes precedes whole-chromosome gains in acute myeloid leukemia.
Leukemia. 2026 Jul 23. doi: 10.1038/s41375-026-03069.
PubMed

BOUCHER AC, Rosikiewicz W, Cotton A, Broadhurst AL, et al
The effect of cohesin mutations on HLA-class II expression in the myeloid leukemia of Down syndrome.
Leukemia. 2026 Jul 21. doi: 10.1038/s41375-026-03074.
PubMed Abstract available

CHEN Z, Cai Y, Wang Y, Lai X, et al
G3BP2 confers venetoclax resistance by stabilizing ELF1-mediated MCL1 transcription in acute myeloid leukemia.
Leukemia. 2026 Jul 20. doi: 10.1038/s41375-026-03063.
PubMed Abstract available

QUINLAN L, Yeung D, Heatley S, White D, et al
Central nervous system involvement in acute lymphoblastic leukemia: pathogenesis and targeted therapy.
Leukemia. 2026 Jul 17. doi: 10.1038/s41375-026-03060.
PubMed Abstract available

TOPP MS, Shah BD, Jabbour E, Park JH, et al
Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Leukemia. 2026 Jul 17. doi: 10.1038/s41375-026-03045.
PubMed Abstract available

CORTES JE, Rea D, Mauro MJ, Hochhaus A, et al
Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results.
Leukemia. 2026 Jul 16. doi: 10.1038/s41375-026-02972.
PubMed Abstract available

ZHANG M, Fields S, Zhang Q, Ouyang Y, et al
Rbm5 sustains leukemia stem cells through a Myc-driven transcriptional circuitry.
Leukemia. 2026 Jul 16. doi: 10.1038/s41375-026-03064.
PubMed Abstract available

AZEVEDO RS, Jabbour E, Jain N, Haddad FG, et al
Predictors of survival in adults with B-cell acute lymphoblastic leukemia treated with blinatumomab and/or inotuzumab ozogamicin in first salvage.
Leukemia. 2026 Jul 16. doi: 10.1038/s41375-026-03056.
PubMed Abstract available

KTORIDOU-VALEN I, Lenartova A, Grondal SM, Wogsland CE, et al
Phase I, open-label, multi-center dose-finding and expansion study to investigate the safety, tolerability, and preliminary efficacy of CR-001 (5-FU-miR-15a) in patients with acute myeloid leukemia.
Leukemia. 2026 Jul 15. doi: 10.1038/s41375-026-03054.
PubMed

ZHANG M, Li Y, Zhang B, Cai C, et al
EIF4A3-dependent nonsense-mediated decay buffers AML1-ETO9a dosage and modulates outcome in t(8;21) acute myeloid leukemia.
Leukemia. 2026 Jul 14. doi: 10.1038/s41375-026-03051.
PubMed Abstract available

VAN DER WERF I, Jamieson CHM
Cancer is an RNA disease: DNA is not destiny, RNA determines leukemia fate.
Leukemia. 2026 Jul 13. doi: 10.1038/s41375-026-03041.
PubMed

HALPERN AB, Othus M, Percival MM, Ghiuzeli C, et al
Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms.
Leukemia. 2026 Jul 13. doi: 10.1038/s41375-026-03044.
PubMed Abstract available

SIMON F, Al-Sawaf O
Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies.
Leukemia. 2026 Jul 7. doi: 10.1038/s41375-026-03012.
PubMed

ZHANG M, Liu L, Fu S, Feng J, et al
CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.
Leukemia. 2026 Jul 3. doi: 10.1038/s41375-026-03017.
PubMed Abstract available

June 2026

WINKLER R, Griesler B, Sippl W, Boon RA, et al
Lineage-restricted dependency on an oncofetal SNHG29-IGF2BP1 RNA axis in acute megakaryoblastic leukemia.
Leukemia. 2026 Jun 30. doi: 10.1038/s41375-026-03040.
PubMed Abstract available

TRABER GM, Mark K, Jayanthan A, Chae HD, et al
Selective targeting of RSK signaling with PMD-026 suppresses FLT3-activated acute myeloid leukemia while sparing normal hematopoiesis.
Leukemia. 2026 Jun 30. doi: 10.1038/s41375-026-03034.
PubMed

GARCIA C, Lyons KU, Contreras JG, Liu T, et al
FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia.
Leukemia. 2026 Jun 30. doi: 10.1038/s41375-026-03030.
PubMed Abstract available

AYYADEVARA VSSA, Perencsik R, Patil S, Gaur S, et al
Selective sensitivity of Ph-like B-cell acute lymphoblastic leukemia to BRG1 inhibition identifies a therapeutic vulnerability.
Leukemia. 2026 Jun 30. doi: 10.1038/s41375-026-03011.
PubMed

WANG Y, Xin Z
Unpacking the epigenetic landscape of acute lymphoblastic leukemia: resolving cellular heterogeneity and nutritional complexities.
Leukemia. 2026 Jun 30. doi: 10.1038/s41375-026-03039.
PubMed

KOVACH AE, Ding YY, Lamble AJ, Bernt K, et al
Plasticity under pressure: biology and detection of lineage switch in acute leukemia.
Leukemia. 2026 Jun 26. doi: 10.1038/s41375-026-03020.
PubMed Abstract available

YAN Y, Zhou Y, Chen W, Wang J, et al
MYD88 variants in chronic lymphocytic leukemia exhibit distinct biological behaviors and prognostic implications.
Leukemia. 2026 Jun 26. doi: 10.1038/s41375-026-03019.
PubMed

HOU Y, Xing Y, Chen C, Su D, et al
Small interfering RNA-mediated silencing of mutant NPM1 suppresses acute myeloid leukemia via reversing KAT7 and p300-mediated histone acetylation.
Leukemia. 2026 Jun 26. doi: 10.1038/s41375-026-03014.
PubMed Abstract available

MANSOUR AG, Huang Y, Pemberton JP, Alsouqi A, et al
Outcomes of patients with chronic lymphocytic leukemia discontinuing covalent Bruton tyrosine kinase inhibitors due to adverse events.
Leukemia. 2026 Jun 25. doi: 10.1038/s41375-026-03005.
PubMed

VASSEUR L, Duployez N, Lambert J, Lapillonne H, et al
Genomic landscape of acute myeloid leukemia in adolescents and young adults.
Leukemia. 2026 Jun 25. doi: 10.1038/s41375-026-03010.
PubMed

YBARRA TK, Sathianathen RS, Hamidi R, Hijiya N, et al
Immunological mechanisms and therapeutic advances in chronic myeloid leukemia.
Leukemia. 2026 Jun 25. doi: 10.1038/s41375-026-03006.
PubMed Abstract available

MAZZERA L, Abeltino M, Lombardi G, Cantoni AM, et al
Retraction Note: MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia.
Leukemia. 2026 Jun 24. doi: 10.1038/s41375-026-03026.
PubMed

RINALDETTI S, Chepeleva M, Hedblom A, Sticht C, et al
Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study.
Leukemia. 2026 Jun 18. doi: 10.1038/s41375-026-03001.
PubMed Abstract available

CICHOCKI F, Felices M, Matson AW, Lee MJ, et al
Can natural killer cells cure leukemia?
Leukemia. 2026 Jun 15. doi: 10.1038/s41375-026-02992.
PubMed

LEE D, Abu-Shihab Y, Plas K, Nicolet D, et al
Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.
Leukemia. 2026 Jun 15. doi: 10.1038/s41375-026-02996.
PubMed Abstract available

OLIVEIRA ML, Nuantang K, Hure G, Avila-Avila A, et al
A novel CD7-directed antibody-drug conjugate targeting BCL-XL with potent anti-leukemic activity in T-cell acute lymphoblastic leukemia.
Leukemia. 2026 Jun 8. doi: 10.1038/s41375-026-02998.
PubMed Abstract available

PICIOCCHI A, Talone A, Messina M, de Fabritiis P, et al
Normal life expectancy after all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Leukemia. 2026 Jun 8. doi: 10.1038/s41375-026-02989.
PubMed

LI AM, Aftandilian C, Annesley C, Colace S, et al
Inotuzumab ozogamicin in individuals with Down syndrome and acute lymphoblastic leukemia.
Leukemia. 2026 Jun 3. doi: 10.1038/s41375-026-02997.
PubMed

CHATTERJEE A, Mustafa Ali MK, Bailey CM, Liu Y, et al
Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors.
Leukemia. 2026 Jun 2. doi: 10.1038/s41375-026-02982.
PubMed Abstract available

AL-ALI HK, Heidel ST, Palandri F, Heidel FH, et al
MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms.
Leukemia. 2026;40:1111-1121.
PubMed Abstract available

May 2026

TAN J, He F, Hu H, Cao W, et al
Unraveling cellular and molecular mechanisms of relapse in CD19/CD22 dual-targeting chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia.
Leukemia. 2026 May 29. doi: 10.1038/s41375-026-02978.
PubMed Abstract available

FUJITA M, Ureshino H
Clonal dynamics and therapeutic pressure in myeloproliferative neoplasm with concomitant chronic myeloid leukemia: Potential implications of JAK2-directed therapy and additional mutations.
Leukemia. 2026 May 29. doi: 10.1038/s41375-026-02983.
PubMed

CHIU A, Seheult JN, Shi M, Jevremovic D, et al
Artificial intelligence-enhancement of flow cytometry data accelerates the identification of measurable residual chronic lymphocytic leukemia.
Leukemia. 2026 May 26. doi: 10.1038/s41375-026-02986.
PubMed Abstract available

HOCHHAUS A, Talpaz M, Saglio G, Cortes JE, et al
From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia.
Leukemia. 2026 May 22. doi: 10.1038/s41375-026-02984.
PubMed Abstract available

GALE RP, Hochhaus A
2001-2026: LEUKEMIA celebrates 25 years of tyrosine kinase inhibitors.
Leukemia. 2026 May 22. doi: 10.1038/s41375-026-02981.
PubMed

DUCOURNEAU B, Pages A, Struski S, Decamp M, et al
Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement.
Leukemia. 2026 May 12. doi: 10.1038/s41375-026-02973.
PubMed Abstract available

WU H, Hu C, Wang A, Weisberg EL, et al
Editorial Expression of Concern: Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia.
Leukemia. 2026 May 6. doi: 10.1038/s41375-026-02980.
PubMed

IIDA K, Nakanishi M, Nakahara J, Asada S, et al
MECOM promotes leukemia progression and inhibits mast cell differentiation through functional competition with GATA2.
Leukemia. 2026 May 5. doi: 10.1038/s41375-026-02977.
PubMed Abstract available

MOHAMED SMA, Schofield P, Evans K, Friedrich KH, et al
A novel CRLF2-targeted antibody-drug conjugate exhibits potent anti-leukemic activity against Ph-like acute lymphoblastic leukemia.
Leukemia. 2026 May 5. doi: 10.1038/s41375-026-02976.
PubMed

DUONG N, Khan DH, Thomas GE, Feng Y, et al
Intracellular IL-23R is necessary for mitotic spindle formation and viability in AML.
Leukemia. 2026;40:906-917.
PubMed Abstract available

April 2026

WANG Y, Li C, Gale RP, Liang Q, et al
Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies.
Leukemia. 2026 Apr 30. doi: 10.1038/s41375-026-02970.
PubMed Abstract available

HODDER A, Mishra A, Enshaei A, Baird S, et al
Reduced-intensity reinduction for children and young persons with relapsed acute lymphoblastic leukemia.
Leukemia. 2026 Apr 30. doi: 10.1038/s41375-026-02923.
PubMed

KAMITORI T, Saida S, Mitani K, Tsujimoto S, et al
Multi-omics analysis of pediatric minimally differentiated acute myeloid leukemia reveals RUNX1-driven stemness and chemoresistance.
Leukemia. 2026 Apr 29. doi: 10.1038/s41375-026-02967.
PubMed Abstract available

AHMIDOUCH M, Deshpande P, Salib C, Brunner P, et al
Chronic myelomonocytic leukemia beyond the marrow: biology, patterns, and management of extramedullary disease.
Leukemia. 2026 Apr 27. doi: 10.1038/s41375-026-02966.
PubMed Abstract available

LERTVIVATPONG N, Inaba H
Blinatumomab in pediatric acute lymphoblastic leukemia: current and future use.
Leukemia. 2026 Apr 27. doi: 10.1038/s41375-026-02962.
PubMed Abstract available

GHETE T, Gaschler L, Krumbholz M, Sembill S, et al
Prevalence and characterization of germline RAS pathway variants in children with chronic myeloid leukemia.
Leukemia. 2026 Apr 24. doi: 10.1038/s41375-026-02952.
PubMed

HOCHHAUS A, le Coutre P, Milojkovic D, Kim DDH, et al
ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors.
Leukemia. 2026 Apr 23. doi: 10.1038/s41375-026-02965.
PubMed Abstract available

DREWES C, Lopez C, Okeke N, Jebaraj B, et al
The spectrum of immunoglobulin heavy chain enhancer hijacking in chronic lymphocytic leukemia.
Leukemia. 2026 Apr 23. doi: 10.1038/s41375-026-02902.
PubMed Abstract available

SABERI M, Delfi O, Hall CJ, Madola DWKK, et al
A transgenic zebrafish leukemia model driven by KMT2A::MLLT3 (MLL-AF9).
Leukemia. 2026 Apr 22. doi: 10.1038/s41375-026-02953.
PubMed

HOUTMAN AH, Arfeuille C, Strullu M, Baruchel A, et al
Genomic fusion breakpoints for DNA-based measurable residual disease monitoring in pediatric acute lymphoblastic leukemia.
Leukemia. 2026 Apr 21. doi: 10.1038/s41375-026-02958.
PubMed Abstract available

ZHANG L, Guo W, Fu YH, Wu D, et al
HDAC8 inhibition targets STAT3-MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia.
Leukemia. 2026 Apr 21. doi: 10.1038/s41375-026-02950.
PubMed Abstract available

KANDARPA M, Peterson LF, Potu H, Ramappan M, et al
Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX models.
Leukemia. 2026 Apr 15. doi: 10.1038/s41375-026-02957.
PubMed Abstract available

NEELAMRAJU Y, Rapaport F, Gandara JA, Paudel BB, et al
Elevated levels of TNF and its targets characterize better-risk older acute myeloid leukemia patients.
Leukemia. 2026 Apr 13. doi: 10.1038/s41375-026-02954.
PubMed

BHATIA S, Hageman L, Chen Y, Wadhwa A, et al
Adherence-enhancing intervention and relapse in childhood acute lymphoblastic leukemia: results from the Children's Oncology Group randomized trial ACCL1033.
Leukemia. 2026 Apr 13. doi: 10.1038/s41375-026-02951.
PubMed

ZHOU C, Bian S, Pang J, Bian H, et al
mRNA vaccination targeting AML1::ETO fusion gene eliminates leukemia cells via activating T cells.
Leukemia. 2026 Apr 10. doi: 10.1038/s41375-026-02940.
PubMed

CHIN KK, Abdul-Hay M, Shukla M, Geyer MB, et al
Overcoming MEN1-mediated resistance with menin inhibitor switching in KMT2A-rearranged acute myeloid leukemia.
Leukemia. 2026 Apr 10. doi: 10.1038/s41375-026-02959.
PubMed

SAJIKI D, Muramatsu H, Wakamatsu M, Tsumura Y, et al
Error-corrected next-generation sequencing for profiling the subclonal genetic architecture of juvenile myelomonocytic leukemia.
Leukemia. 2026 Apr 7. doi: 10.1038/s41375-026-02922.
PubMed

March 2026

TIAN Z, Gao P, Zhang Y, Ma J, et al
PRMT1 facilitates the tumorigenesis of chronic lymphocytic leukemia by regulating methylation of MAST1.
Leukemia. 2026 Mar 30. doi: 10.1038/s41375-026-02935.
PubMed Abstract available

PARK J, Kim SH, Park J, Park H, et al
BCR::ABL1 tyrosine kinase inhibitors induce ribosome collisions to activate ZAK-dependent ribotoxic stress and apoptosis in chronic myeloid leukemia.
Leukemia. 2026 Mar 30. doi: 10.1038/s41375-026-02916.
PubMed Abstract available

PERUSINI MA, Pagnano K, Pavlovsky C, Zackova D, et al
The adverse prognostic impact of HMGCLL1 gene variants can be abrogated by frontline second-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Leukemia. 2026 Mar 30. doi: 10.1038/s41375-026-02921.
PubMed

KIRCHHOFF H, Schoenherr C, Fleischer L, Talbot SR, et al
Differential mitochondrial priming by BCR::ABL1 in B-cell precursor acute lymphoblastic leukemia.
Leukemia. 2026 Mar 30. doi: 10.1038/s41375-026-02944.
PubMed

GAGNON LL, Duminuco A, Stagno F, Sobas M, et al
Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes.
Leukemia. 2026 Mar 27. doi: 10.1038/s41375-026-02928.
PubMed Abstract available

LI YR, Shen X, Chen Y, Zhu Y, et al
Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of acute myeloid leukemia.
Leukemia. 2026 Mar 26. doi: 10.1038/s41375-026-02930.
PubMed Abstract available

VASSEUR L, Duchmann M, Duployez N, Raffoux E, et al
Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia.
Leukemia. 2026 Mar 26. doi: 10.1038/s41375-026-02900.
PubMed Abstract available

ARYAL S, Curtiss BM, Zhou X, Lu R, et al
A Perturb-seq map of a differentiation hub reveals synergistic vulnerabilities in KMT2A-rearranged acute myeloid leukemia.
Leukemia. 2026 Mar 25. doi: 10.1038/s41375-026-02917.
PubMed Abstract available

TU Y, Cai X, Tao Z, Zhang R, et al
Discovery of a selective CDK7 PROTAC against acute leukemia with low platelet toxicity.
Leukemia. 2026 Mar 25. doi: 10.1038/s41375-026-02925.
PubMed Abstract available

NICKELS EM, Morimoto LM, Kang AY, Metayer C, et al
The impact of periconceptional folate on the DNA methylome of acute lymphoblastic leukemia.
Leukemia. 2026 Mar 24. doi: 10.1038/s41375-026-02866.
PubMed Abstract available

FASCI A, Vallone FE, Nabelsi N, Viry E, et al
Functional cooperation between the B-cell receptor and NOTCH1 in regulating metabolic reprogramming in chronic lymphocytic leukemia.
Leukemia. 2026 Mar 23. doi: 10.1038/s41375-026-02912.
PubMed Abstract available

BARRAL L, Lespinasse N, Martin Cardozo C, Jeanpierre S, et al
Targeting BMP and TAZ/TEAD mechanotransduction pathways impairs acute myeloid leukemia chemoresistance.
Leukemia. 2026 Mar 18. doi: 10.1038/s41375-026-02904.
PubMed Abstract available

WOBST J, Ruge H, Senk S, Muller H, et al
Multiple myeloma with concomitant chronic lymphocytic leukemia: evidence for independent clonal origin.
Leukemia. 2026 Mar 18. doi: 10.1038/s41375-026-02918.
PubMed

PARKER H, Carr L, Norris K, Nilsson-Takeuchi A, et al
High-risk molecular features may eclipse genomic complexity in predicting chronic lymphocytic leukemia outcomes; UK clinical trial insights.
Leukemia. 2026 Mar 11. doi: 10.1038/s41375-026-02906.
PubMed Abstract available

LOGHAVI S, Farhat A, Jamison TJ, El Hajjar G, et al
Immunophenotypic changes following menin inhibition in acute myeloid leukemia.
Leukemia. 2026 Mar 11. doi: 10.1038/s41375-026-02905.
PubMed Abstract available

SELIMOGLU-BUET D, Chevret S, Santini V, Thepot S, et al
Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?
Leukemia. 2026 Mar 9. doi: 10.1038/s41375-026-02901.
PubMed Abstract available

SMALLBONE P, Cao K, Saliba RM, Carmarzzi Y, et al
Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.
Leukemia. 2026 Mar 9. doi: 10.1038/s41375-026-02907.
PubMed Abstract available

ZHANG L, Han Q, Xiang H, Lapalombella R, et al
Enhancing tyrosine kinase inhibitor sensitivity by restoring IKAROS activity on GLUT1 expression and glycolysis in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leukemia. 2026 Mar 6. doi: 10.1038/s41375-026-02898.
PubMed Abstract available

SETIAWAN T, Muhammad JA, Julianto NM, Wirawan LM, et al
Correction: Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.
Leukemia. 2026 Mar 5. doi: 10.1038/s41375-026-02909.
PubMed

TIONG IS, Hunter S, Kankanige Y, Mehta NN, et al
Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasets.
Leukemia. 2026;40:649-660.
PubMed Abstract available

GUO Y, Sui P, Yang H, Zhu G, et al
Phf6 truncating mutation drives leukemogenesis via disrupted epigenetic regulation in mice.
Leukemia. 2026;40:594-608.
PubMed Abstract available

SOBERON V, Osswald L, Moore A, Sosnowska D, et al
Strong constitutive NF-kappaB signaling in B cells drives SLL/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.
Leukemia. 2026;40:522-539.
PubMed Abstract available

CAMIOLO G, Gonzalez Silvera D, Leah T, Schwaller J, et al
CSF1R marks a subset of foetal haematopoietic multipotent progenitor cells with acute myeloid leukaemia propagation properties.
Leukemia. 2026;40:540-552.
PubMed Abstract available

CHONABAYASHI K, Iwasaki M, Kanda J, Takamori H, et al
NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.
Leukemia. 2026;40:491-501.
PubMed Abstract available

February 2026

BOHRA A, Hassan R, Zanwar S, Jevremovic D, et al
Correction: Peripheral blood flow cytometry-based definition of plasma cell leukemia.
Leukemia. 2026 Feb 25. doi: 10.1038/s41375-026-02897.
PubMed

LECORNEC N, Rabian F, Dourthe ME, Chevillon F, et al
Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia.
Leukemia. 2026 Feb 24. doi: 10.1038/s41375-026-02867.
PubMed Abstract available

LAUSEKER M, Sacha T, Klamova H, Yakoleva J, et al
Development of a prognostic scoring system for chronic myeloid leukemia in blast phase.
Leukemia. 2026 Feb 19. doi: 10.1038/s41375-026-02875.
PubMed Abstract available

WANG C, Ge S, Gao J, Yang R, et al
The fragile equilibrium of cancer latency: lessons from spontaneous remission in congenital leukemia.
Leukemia. 2026 Feb 17. doi: 10.1038/s41375-026-02888.
PubMed

CHAKRABORTY S, Morganti C, Zaldana K, Rivera Pena B, et al
A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia.
Leukemia. 2026 Feb 17. doi: 10.1038/s41375-026-02883.
PubMed Abstract available

NIELSEN CG, Als-Nielsen B, Albertsen BK, Davidsson OB, et al
Severe toxicity-free survival following acute lymphoblastic leukemia in patients aged 1-45 years: a Danish cohort study.
Leukemia. 2026 Feb 10. doi: 10.1038/s41375-026-02873.
PubMed Abstract available

MECKLENBRAUCK R, Villaverde Ramiro A, Strang E, Gabdoulline R, et al
Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.
Leukemia. 2026 Feb 9. doi: 10.1038/s41375-026-02874.
PubMed Abstract available

BIRDWELL CE, Fiskus W, Mill CP, Kadia TM, et al
BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.
Leukemia. 2026;40:304-313.
PubMed Abstract available

FULLIN J, Topcu E, Zielinska KA, Schimmer RR, et al
The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis.
Leukemia. 2026;40:279-292.
PubMed Abstract available

January 2026

OEHLER VG, Sala-Torra O, Gilderman N, Beppu L, et al
Next-generation sequencing from chronic myeloid leukemia dried blood spots: insights and implications for global oncology.
Leukemia. 2026 Jan 23. doi: 10.1038/s41375-025-02852.
PubMed Abstract available

WANG Y, Wang X, Li M, Song H, et al
Distal enhancer RNAs regulate alternative promoter usage of MYB and drug resistance in human leukemia cells.
Leukemia. 2026 Jan 22. doi: 10.1038/s41375-026-02862.
PubMed Abstract available

ANSUINELLI M, Peragine N, De Propris MS, Puzzolo MC, et al
Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia.
Leukemia. 2026 Jan 22. doi: 10.1038/s41375-025-02855.
PubMed Abstract available

REA D, Kyrcz-Krzemien S, Sportoletti P, Mayer J, et al
Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results.
Leukemia. 2026 Jan 19. doi: 10.1038/s41375-025-02847.
PubMed Abstract available

HERNANDEZ-SANCHEZ A, Villaverde Ramiro A, Strang E, Turki AT, et al
Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia - a HARMONY study.
Leukemia. 2026 Jan 14. doi: 10.1038/s41375-025-02851.
PubMed Abstract available

BURCHERT A, Nicolini FE, le Coutre P, Saussele S, et al
Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).
Leukemia. 2026 Jan 12. doi: 10.1038/s41375-025-02859.
PubMed Abstract available

GONZALES F, Schneider C, Alexe G, Lin S, et al
Identifying targeted therapies for CBFA2T3::GLIS2 acute myeloid leukemia.
Leukemia. 2026 Jan 8. doi: 10.1038/s41375-025-02845.
PubMed Abstract available

AGATHANGELIDIS A, Iatrou A, Pechlivanis N, Karakatsoulis G, et al
Molecular and functional characterization of the B-cell receptor in chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis.
Leukemia. 2026 Jan 7. doi: 10.1038/s41375-025-02797.
PubMed

AYOUB M, Hitier C, Dehgane L, Mallet E, et al
Olaparib sensitizes chronic lymphocytic leukemia to BTK- and BCL2-targeted therapies via PARP1-independent mitochondrial metabolic dysfunction.
Leukemia. 2026 Jan 7. doi: 10.1038/s41375-025-02846.
PubMed

FUJIMOTO A, Maeda T, Doki N, Fukuhara N, et al
Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.
Leukemia. 2026 Jan 7. doi: 10.1038/s41375-025-02854.
PubMed Abstract available

GURNARI C, Makishima H, Durmaz A, Attardi E, et al
DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.
Leukemia. 2026;40:178-187.
PubMed Abstract available

BILL M, Eckardt JN, Dohner K, Rohnert MA, et al
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.
Leukemia. 2026;40:63-71.
PubMed Abstract available

December 2025

YANG Y, Liu X, Wei J, Qin J, et al
In vivo expression of CD3/CD19 bispecific T-cell engager and alpha-PD-L1-Fc enables effective and durable immunotherapy for CD19(+)/PD-L1(+) leukemia.
Leukemia. 2025 Dec 23. doi: 10.1038/s41375-025-02832.
PubMed Abstract available

DINH TTT, Lordo MR, Zhang AY, Goda C, et al
Leukemia-driven expansion of type 3 innate lymphoid cell facilitates a pro-tumoral microenvironment in acute myeloid leukemia.
Leukemia. 2025 Dec 22. doi: 10.1038/s41375-025-02829.
PubMed Abstract available

HO TC, LaMere MW, Kawano H, Byun DK, et al
Targeting IL-1/IRAK1/4 signaling in acute myeloid leukemia stem cells following treatment and relapse.
Leukemia. 2025 Dec 19. doi: 10.1038/s41375-025-02816.
PubMed Abstract available

ERNST P, Lohse C, Lauseker M, Geissler J, et al
Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspective.
Leukemia. 2025 Dec 19. doi: 10.1038/s41375-025-02826.
PubMed Abstract available

FEDENKO A, Czapinska H, Kramer A, Stolzel F, et al
Etiology of TP53 mutated complex karyotype acute myeloid leukemia.
Leukemia. 2025 Dec 19. doi: 10.1038/s41375-025-02835.
PubMed Abstract available

STRUCKMAN NE, Koutsoumpli G, de Jong RCM, van der Lee DI, et al
A T-cell receptor targeting RUNX1 frameshift mutations in acute myeloid leukemia.
Leukemia. 2025 Dec 12. doi: 10.1038/s41375-025-02817.
PubMed Abstract available

DINARDO CD, Jen WY, Takahashi K, Kadia TM, et al
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
Leukemia. 2025 Dec 10. doi: 10.1038/s41375-025-02827.
PubMed

HAAKSMA LH, Palmieri R, Reuvekamp T, Tettero JM, et al
Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia.
Leukemia. 2025 Dec 10. doi: 10.1038/s41375-025-02825.
PubMed

DEHGANE L, Mallet E, Brasseur C, Krzisch D, et al
REL overexpression and sustained NF-kappaB signaling associated with 2p gain induce resistance to BTK inhibitors in Chronic Lymphocytic Leukemia.
Leukemia. 2025 Dec 9. doi: 10.1038/s41375-025-02818.
PubMed Abstract available

HOCHHAUS A, Gale RP
40 years of LEUKEMIA.
Leukemia. 2025 Dec 8. doi: 10.1038/s41375-025-02840.
PubMed

MIKKELSEN T, Helenius M, Ampatzidou M, Attarbaschi A, et al
Role of common host genome variants in Childhood Acute Lymphoblastic Leukemia.
Leukemia. 2025 Dec 8. doi: 10.1038/s41375-025-02804.
PubMed Abstract available

TEDESCHI A, Frustaci AM, Menna P, Minotti G, et al
Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.
Leukemia. 2025 Dec 2. doi: 10.1038/s41375-025-02824.
PubMed

KADIRKAMANATHAN R, Georgiadis C, Kloos A, Joshi A, et al
Base edited "universal" donor CAR T-cell strategies for acute myeloid leukaemia.
Leukemia. 2025;39:2978-2987.
PubMed Abstract available

ELEFTHERIOU M, Russell J, Tzelepis K
Epitranscriptomic advances in normal and malignant hematopoiesis.
Leukemia. 2025;39:2848-2857.
PubMed Abstract available

PURHONEN M, Tatun M, Luukkainen K, Hung K, et al
Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML.
Leukemia. 2025;39:2968-2977.
PubMed Abstract available

KARAKASLAR EO, Argiro EM, Struckman NE, Shirali Hz R, et al
Resolving inter- and intra-patient heterogeneity in NPM1-mutated AML at single-cell resolution.
Leukemia. 2025;39:2916-2925.
PubMed Abstract available

BAKEWELL J, Moorman AV, Ryan SL
DUX4-rearranged B-ALL: deciphering a biological and clinical conundrum.
Leukemia. 2025;39:2835-2847.
PubMed Abstract available

MIRAKI-MOUD F, Ariza-McNaughton L, KoKo T, Othman J, et al
Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival.
Leukemia. 2025;39:2895-2906.
PubMed Abstract available

November 2025

CASTAGNETTI F, Breccia M, Abruzzese E, Bassan R, et al
Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.
Leukemia. 2025 Nov 18. doi: 10.1038/s41375-025-02796.
PubMed Abstract available

SUI P, Li Y, Hong J, Delma CR, et al
Oncogenic activation of EVC/EVC2 defines a therapeutically targetable subset of acute myeloid leukemia.
Leukemia. 2025 Nov 17. doi: 10.1038/s41375-025-02803.
PubMed Abstract available

LOCATELLI F, Rizzari C, Gruhn B, Klingebiel T, et al
Blinatumomab consolidation in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia: final 5-year follow-up analysis of a randomized multicenter phase 3 study.
Leukemia. 2025 Nov 13. doi: 10.1038/s41375-025-02800.
PubMed

ZHENG H, Zhang L, Li L
Correspondence to "Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis".
Leukemia. 2025 Nov 12. doi: 10.1038/s41375-025-02812.
PubMed

DHIR A, Ethell A, Watkins R, Lam C, et al
The splicing factor PTBP1 interacts with RUNX1 and is required for leukemia cell survival.
Leukemia. 2025 Nov 10. doi: 10.1038/s41375-025-02799.
PubMed Abstract available

OHLSTROM D, Bakhtiari M, Mumme H, Michaud M, et al
Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML.
Leukemia. 2025;39:2721-2734.
PubMed Abstract available

ZAZA A, Zardo G, Banella C, Tucci S, et al
PML::RARalpha+ myeloid cells display metabolic alterations that can be targeted to treat resistant/relapse acute promyelocytic leukemias.
Leukemia. 2025;39:2708-2720.
PubMed Abstract available

PATEL SA, Bennett JM
The evolving nosology of myeloid neoplasms: the semi-centennial of the 1976 French-American-British classification.
Leukemia. 2025;39:2603-2609.
PubMed Abstract available

ZIMOLOVA V, Burocziova M, Berkova L, Grusanovic S, et al
Germline Jak2-R1063H mutation interferes with normal hematopoietic development and increases risk of thrombosis and leukemic transformation.
Leukemia. 2025;39:2745-2757.
PubMed Abstract available

October 2025

GREINER J, Schuler PJ, Schrezenmeier H, Weiss J, et al
Different immunotherapeutic combinations enhance specific T cell immune responses against leukemic cells, as well as leukemic progenitor cells, in acute myeloid leukemia.
Leukemia. 2025 Oct 27. doi: 10.1038/s41375-025-02764.
PubMed Abstract available

NIKKILA A, Lohi O, Abrahamsson J, Griskevicius L, et al
Intensive chemotherapy for high-risk acute lymphoblastic leukemia in first remission: results from the NOPHO ALL2008 study.
Leukemia. 2025 Oct 27. doi: 10.1038/s41375-025-02789.
PubMed

VU TT, Stolzel F, Wang KW, Rollig C, et al
Correction: miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia.
Leukemia. 2025 Oct 17. doi: 10.1038/s41375-025-02788.
PubMed

GOODMAN SJ, Butcher DT, Guger SL, Diehl E, et al
DNA methylation alterations in acute lymphoblastic leukemia survivors with late neurocognitive deficits.
Leukemia. 2025 Oct 17. doi: 10.1038/s41375-025-02779.
PubMed

GEELS J, van Rhenen A, Gradowska P, Asselbergs FW, et al
Heart failure in patients with acute myeloid leukemia (AML) treated with anthracycline agents during remission induction therapy: a systematic review and meta-analysis.
Leukemia. 2025 Oct 10. doi: 10.1038/s41375-025-02753.
PubMed Abstract available

VOSS RK, Pastor Loyola VB, Cardenas MF, Kumar P, et al
Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment.
Leukemia. 2025 Oct 7. doi: 10.1038/s41375-025-02774.
PubMed Abstract available

HUND I, Hess ME, Andrieux G, Stomper J, et al
Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial.
Leukemia. 2025 Oct 7. doi: 10.1038/s41375-025-02780.
PubMed

TAMAI H, Miyake K, Miyake N, Asano J, et al
Combined treatment with amlexanox and cytarabine induces apoptosis via the S100A6-Akt pathway in KMT2A::AFF1-positive acute lymphoblastic leukemia.
Leukemia. 2025 Oct 6. doi: 10.1038/s41375-025-02782.
PubMed

TEDESCHI A, Frustaci AM, Menna P, Minotti G, et al
Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.
Leukemia. 2025 Oct 2. doi: 10.1038/s41375-025-02778.
PubMed

SETIAWAN T, Muhammad JA, Marcellina N, Wirawan LM, et al
Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.
Leukemia. 2025 Oct 1. doi: 10.1038/s41375-025-02768.
PubMed Abstract available

SMITH C, Charbonnier G, Simonin M, Balducci E, et al
Towards methylation-based redefinition of TAL1 positive T-cell acute lymphoblastic leukaemia (T-ALL).
Leukemia. 2025;39:2344-2354.
PubMed Abstract available

KAPAHNKE K, Plenge T, Klaus T, Gupta MK, et al
The histone-methyltransferase DOT1L cooperates with LSD1 to control cell division in blast-phase MPN.
Leukemia. 2025;39:2406-2418.
PubMed Abstract available

PEREZ-AMILL L, Armand-Ugon M, Val-Casals M, Martin-Herreros B, et al
A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias.
Leukemia. 2025;39:2432-2441.
PubMed Abstract available

MOINARD S, Lebecque B, Lachaise T, Johnson-Ansah H, et al
Evaluating a predictive model of tyrosine kinase inhibitor therapy failure in a European-type cohort: a step towards population-specific tools.
Leukemia. 2025;39:2375-2383.
PubMed Abstract available

TIRTAKUSUMA R, Ghonim MA, Schattgen S, Muller B, et al
Endogenous T cell responses to fusion-derived neoantigens in pediatric acute leukemias.
Leukemia. 2025;39:2419-2431.
PubMed Abstract available

ZHANG X, Li M, Chen Y, Liu J, et al
Deubiquitinase USP6 stabilizes oncogenic RUNX1 fusion proteins to promote the leukemic potential and malignant progression.
Leukemia. 2025;39:2355-2363.
PubMed Abstract available

September 2025

VISENTIN A, Gaffo E, Furstenau M, Rogers KA, et al
Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study.
Leukemia. 2025 Sep 19. doi: 10.1038/s41375-025-02755.
PubMed Abstract available

MAZZEO P, Penir SM, Shumilov E, Wolf S, et al
Clonal evolution and apoptosis resistance in myelodysplastic neoplasms and acute myeloid leukemia under treatment: insights from integrative longitudinal profiling.
Leukemia. 2025 Sep 19. doi: 10.1038/s41375-025-02756.
PubMed Abstract available

CUSAN M, Larkin K, Nicolet D, Jurinovic V, et al
Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology).
Leukemia. 2025 Sep 19. doi: 10.1038/s41375-025-02644.
PubMed Abstract available

POLLYEA D, Kerre T, Deeren D, Beguin Y, et al
Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia.
Leukemia. 2025 Sep 15. doi: 10.1038/s41375-025-02767.
PubMed Abstract available

MIRANDA-GALVIS M, Tjioe KC, Sharara M, Maloney M, et al
Estimating the burden of chronic stress through allostatic load in patients with chronic myeloid leukemia.
Leukemia. 2025 Sep 11. doi: 10.1038/s41375-025-02763.
PubMed Abstract available

KANARI M, Jimenez Garcia I, Steffen FD, Krattiger LA, et al
A three-dimensional ex vivo model recapitulates in vivo features and drug resistance phenotypes in childhood acute lymphoblastic leukemia.
Leukemia. 2025 Sep 10. doi: 10.1038/s41375-025-02739.
PubMed Abstract available

GONG X, Liu W, Liu Y, Fang Q, et al
Correction: Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial.
Leukemia. 2025 Sep 5. doi: 10.1038/s41375-025-02696.
PubMed

VENDITTI A, Hou JZ, Fenaux P, Jonas BA, et al
Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model.
Leukemia. 2025 Sep 5. doi: 10.1038/s41375-025-02730.
PubMed Abstract available

MOCKING TR, Haaksma LH, Reuvekamp T, Kelder A, et al
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial.
Leukemia. 2025 Sep 3. doi: 10.1038/s41375-025-02747.
PubMed

XU G, Wang F, Chen M, Gao W, et al
Targeting HDAC8 sensitizes tyrosine kinase inhibitors in the elimination of B-cell acute lymphoblastic leukemia cells through degradation of HIF-1alpha.
Leukemia. 2025 Sep 2. doi: 10.1038/s41375-025-02749.
PubMed Abstract available

RONNACKER J, Muller PJ, Mikesch JH, Zukunft S, et al
Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis.
Leukemia. 2025;39:2174-2180.
PubMed Abstract available

BERTOLI R, Cao D, Tuckey O, Gammell S, et al
5-Azacytidine and decitabine induce C > G transversions in both murine and human cells.
Leukemia. 2025;39:2112-2124.
PubMed Abstract available

VICK EJ, Hassan A, Choi K, Bennett J, et al
Targeting of IRAK4 and GSPT1 enhances therapeutic efficacy in AML via c-Myc destabilization.
Leukemia. 2025;39:2163-2173.
PubMed Abstract available

CALDERON AS, Ghazanfari R, Masoumi Z, Kharazi S, et al
Ontogeny-specific induction of the KMT2A::AFF1-fusion drives development of a distinct CD24 positive pre-leukemic state.
Leukemia. 2025;39:2099-2111.
PubMed Abstract available

NADEU F, Shuai S, Clot G, Hilton LK, et al
Disease-specific U1 spliceosomal RNA mutations in mature B-cell neoplasms.
Leukemia. 2025;39:2076-2086.
PubMed Abstract available

ALFONSO-PIEROLA A, Martinez-Cuadron D, Rodriguez-Veiga R, Gil C, et al
Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry.
Leukemia. 2025 Sep 1. doi: 10.1038/s41375-025-02744.
PubMed Abstract available

August 2025

CURIK N, Laznicka A, Krizkova J, Suchankova P, et al
Venetoclax in combination with ponatinib for the treatment of asciminib-resistant chronic myeloid leukemia.
Leukemia. 2025 Aug 26. doi: 10.1038/s41375-025-02732.
PubMed

HLEIHEL R, Skayneh H, Wu HC, Hamie M, et al
Retinoic acid disrupts an NPM1c/ROS/SENP3/ARF oncogenic axis in acute myeloid leukemia.
Leukemia. 2025 Aug 26. doi: 10.1038/s41375-025-02731.
PubMed Abstract available

TELZEROW E, Gorlich D, Sauerland C, Rothenberg-Thurley M, et al
Quality of life and life satisfaction in long-term survivors of acute myeloid leukemia.
Leukemia. 2025 Aug 22. doi: 10.1038/s41375-025-02735.
PubMed Abstract available

ZHENG J, Jin L, Chen Y, Duan Y, et al
Targeting p16(INK4a)-mediated cellular senescence as a therapeutic strategy for FLT3-ITD-driven acute myeloid leukemia.
Leukemia. 2025 Aug 21. doi: 10.1038/s41375-025-02743.
PubMed Abstract available

FERRAO BLANCO MN, Kazybay B, Belderbos M, Heidenreich O, et al
Distinct stromal cell populations define the B-cell acute lymphoblastic leukemia microenvironment.
Leukemia. 2025 Aug 15. doi: 10.1038/s41375-025-02734.
PubMed Abstract available

AMARAL P, Christie R, Gresham DOF, Lucas EJM, et al
Underlying biology, challenges and emergent concepts in the treatment of relapsed and refractory pediatric T-cell acute lymphoblastic leukemia.
Leukemia. 2025 Aug 14. doi: 10.1038/s41375-025-02723.
PubMed Abstract available

WU K, Liu H, Hu W, Liu Y, et al
Clinically associated genomic landscape of pediatric non-Down Syndrome acute megakaryoblastic leukemia in Chinese patients.
Leukemia. 2025 Aug 11. doi: 10.1038/s41375-025-02741.
PubMed

SUZUKI K, Kusayanagi S, Kuze Y, Hata M, et al
Bidirectional anti-tumor and immunological strategies by targeting GARP-TGF-beta axis in adult T-cell leukemia/lymphoma.
Leukemia. 2025 Aug 4. doi: 10.1038/s41375-025-02725.
PubMed Abstract available

EHRMANN AS, Quijada-Alamo M, Close V, Guo M, et al
NOTCH1 signaling is dysregulated by loss of the deubiquitinase USP28 with del(11q), uncovering USP28 inhibition as novel therapeutic target in CLL.
Leukemia. 2025;39:1892-1904.
PubMed Abstract available

YAN J, Shi C, Yang G, Tian Z, et al
T cell receptor mimic CAR T cells targeting cathepsin G signal peptide.
Leukemia. 2025;39:1948-1959.
PubMed Abstract available

BERG V, Lollies A, Schneider M, Johansson P, et al
Common origin and somatic mutation patterns of composite lymphomas and leukemias.
Leukemia. 2025;39:1960-1971.
PubMed Abstract available

ZOU J, Kinosada H, Takayanagi SI, Ishii T, et al
KK2845, a PBD dimer-containing antibody-drug conjugate targeting TIM-3-expressing AML.
Leukemia. 2025;39:1848-1856.
PubMed Abstract available

July 2025

CALABRETTO G, Binatti A, Teramo A, Buratin A, et al
Transcriptomic landscape of CD8+ and CD4 + T-LGL leukemia revealed the distinct impact of STAT3 and STAT5B activating mutations.
Leukemia. 2025 Jul 28. doi: 10.1038/s41375-025-02708.
PubMed Abstract available

LIEBER MR, Hsieh CL
On the mechanism of NPM1 mutations in acute myeloid leukemia.
Leukemia. 2025 Jul 28. doi: 10.1038/s41375-025-02722.
PubMed

YANG C, Kang YY, Zhu CY, Ma Y, et al
Heat stress targets and degrades BCR::ABL1 oncoproteins to overcome drug-resistance in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leukemia. 2025 Jul 22. doi: 10.1038/s41375-025-02709.
PubMed Abstract available

BOND DR, Burnard SM, Uddipto K, Hunt KV, et al
Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for acute myeloid leukemia cell self-renewal.
Leukemia. 2025 Jul 17. doi: 10.1038/s41375-025-02693.
PubMed

KELEKCI S, Kelly K, Goyal A, Wehrwein N, et al
DNA demethylation-mediated downregulation of MNX1 in acute myeloid leukemia.
Leukemia. 2025 Jul 14. doi: 10.1038/s41375-025-02680.
PubMed

ZHAO Y, Cao W, Shi J, Cao Y, et al
Impact of TP53 variants and germline mutations on allogeneic stem cell transplantation outcomes in acute myeloid leukemia and myelodysplastic neoplasms.
Leukemia. 2025 Jul 14. doi: 10.1038/s41375-025-02672.
PubMed

APPERLEY JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, et al
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.
Leukemia. 2025 Jul 11. doi: 10.1038/s41375-025-02664.
PubMed Abstract available

RETTINGER E, Heckl D, Gibson B, Sauer M, et al
The hallmarks of hematopoietic stem cell transplantation for pediatric acute myeloid leukemia.
Leukemia. 2025 Jul 9. doi: 10.1038/s41375-025-02685.
PubMed Abstract available

SKULI SJ, Bakayoko A, Kruidenier M, Manning B, et al
Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response.
Leukemia. 2025 Jul 9. doi: 10.1038/s41375-025-02668.
PubMed Abstract available

OKSA L, Moisio S, Maqbool K, Kramer R, et al
Genomic determinants of therapy response in ETV6::RUNX1 leukemia.
Leukemia. 2025 Jul 9. doi: 10.1038/s41375-025-02683.
PubMed Abstract available

RONNACKER J, Ruhnke L, Rollig C, Middeke JM, et al
Induction chemotherapy with CPX-351 in acute myeloid leukemia: revisiting the role of early bone marrow assessment.
Leukemia. 2025 Jul 3. doi: 10.1038/s41375-025-02675.
PubMed

June 2025

GONG X, Liu W, Liu Y, Fang Q, et al
Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial.
Leukemia. 2025 Jun 30. doi: 10.1038/s41375-025-02674.
PubMed Abstract available

WANG M, Zhu R, Small D, Lin L, et al
SIRT5 inhibition impairs mitochondrial metabolism and enhances venetoclax-induced elimination of acute myeloid leukemia cells.
Leukemia. 2025 Jun 30. doi: 10.1038/s41375-025-02673.
PubMed Abstract available

GRASSI F, Singh M, Moussaud S, Rodriguez GV, et al
DCPS is a synthetic lethal therapeutic target in acute myeloid leukemia expressing low levels of FHIT.
Leukemia. 2025 Jun 26. doi: 10.1038/s41375-025-02661.
PubMed

WELCH BM, Parikh SA, Kay NE, Medina KL, et al
Profound phenotypic deficiencies in mature blood and bone marrow progenitor dendritic cells in chronic lymphocytic leukemia patients.
Leukemia. 2025 Jun 26. doi: 10.1038/s41375-025-02579.
PubMed Abstract available

PEPE S, Vitale C, Giannarelli D, Visentin A, et al
Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes.
Leukemia. 2025 Jun 25. doi: 10.1038/s41375-025-02666.
PubMed Abstract available

YU H, Hong J, Shin DY, Lee CH, et al
The role of ASXL1, SRSF2, and EZH2 mutations in chromatin dysregulation of myelodysplastic neoplasia and acute myeloid leukemia.
Leukemia. 2025 Jun 25. doi: 10.1038/s41375-025-02657.
PubMed Abstract available

DING Y, He B, Bogush D, Schramm J, et al
Critical roles of IKAROS and HDAC1 in regulation of heterochromatin and tumor suppression in T-cell acute lymphoblastic leukemia.
Leukemia. 2025 Jun 24. doi: 10.1038/s41375-025-02651.
PubMed Abstract available

CSIZMAR CM, Natu A, Gurney M, Fathima S, et al
Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes.
Leukemia. 2025 Jun 24. doi: 10.1038/s41375-025-02648.
PubMed

BLOMBERY P, Chatzikonstantinou T, Gerousi M, Rosenquist R, et al
Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice.
Leukemia. 2025 Jun 24. doi: 10.1038/s41375-025-02662.
PubMed Abstract available

LEBON D, Da Rocha A, Cassinat B, Heiblig M, et al
Comparison of induction with arsenic trioxide or chemotherapy in a real-world cohort of patients with high-risk acute promyelocytic leukemia.
Leukemia. 2025 Jun 24. doi: 10.1038/s41375-025-02663.
PubMed Abstract available

MASHIMA K, Kuang Y, Fernandes SM, Xu S, et al
Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia.
Leukemia. 2025 Jun 23. doi: 10.1038/s41375-025-02611.
PubMed

VIT F, Bittolo T, Zucchetto A, Papotti R, et al
Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemia.
Leukemia. 2025 Jun 18. doi: 10.1038/s41375-025-02650.
PubMed Abstract available

IKOMA Y, Nakamura N, Kaneda Y, Takamori H, et al
Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML.
Leukemia. 2025;39:1362-1367.
PubMed Abstract available

BUCKLEY M, Yeung DT, White DL, Eadie LN, et al
T-cell acute lymphoblastic leukaemia: subtype prevalence, clinical outcome, and emerging targeted treatments.
Leukemia. 2025;39:1294-1310.
PubMed Abstract available

VELETIC I, Harris DM, Rozovski U, Bertilaccio MTS, et al
CLL cell-derived exosomes alter the immune and hematopoietic systems.
Leukemia. 2025;39:1380-1394.
PubMed Abstract available

May 2025

ZHANG Y, Feng Z, Du J, Liu H, et al
High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trial.
Leukemia. 2025 May 28. doi: 10.1038/s41375-025-02655.
PubMed Abstract available

BOHRA A, Hassan R, Zanwar S, Jevremovic D, et al
Peripheral Blood Flow Cytometry-based Definition of Plasma Cell Leukemia.
Leukemia. 2025 May 26. doi: 10.1038/s41375-025-02653.
PubMed

DEMBITZ V, James SC, Gallipoli P
Targeting lipid metabolism in acute myeloid leukemia: biological insights and therapeutic opportunities.
Leukemia. 2025 May 22. doi: 10.1038/s41375-025-02645.
PubMed Abstract available

AUER F, Morcos MNF, Sipola M, Akhtar I, et al
Trajectories from single-cells to PAX5-driven leukemia reveal PAX5-MYC interplay in vivo.
Leukemia. 2025 May 20. doi: 10.1038/s41375-025-02626.
PubMed Abstract available

KUHN MWM, Pemmaraju N, Heidel FH
The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms.
Leukemia. 2025 May 15. doi: 10.1038/s41375-025-02639.
PubMed Abstract available

NGUYEN NTK, Yao H, Hosokawa K, Esaki Y, et al
Acute myeloid leukemia stem cells remodel the bone marrow niche via TGF-beta-activated Alcam(+) bone lining cells, creating a self-sustaining environment.
Leukemia. 2025 May 13. doi: 10.1038/s41375-025-02640.
PubMed

WANG'ONDU RW, Ashcraft E, Chang TC, Roberts KG, et al
Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia.
Leukemia. 2025 May 13. doi: 10.1038/s41375-025-02633.
PubMed Abstract available

BATALLER A, Goulart HE, Issa GC, DiNardo CD, et al
Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements.
Leukemia. 2025 May 9. doi: 10.1038/s41375-025-02634.
PubMed Abstract available

IZUMI S, Ohtani K, Matsumoto M, Shibata S, et al
Regulation of H3K4me3 breadth and MYC expression by the SETD1B catalytic domain in MLL-rearranged leukemia.
Leukemia. 2025 May 8. doi: 10.1038/s41375-025-02638.
PubMed Abstract available

NGUYEN LXT, Zhang B, Hoang DH, Zhao D, et al
Correction: Cytoplasmic DROSHA and non-canonical mechanisms of MiR-155 biogenesis in FLT3-ITD acute myeloid leukemia.
Leukemia. 2025 May 5. doi: 10.1038/s41375-025-02637.
PubMed

LAUSEKER M, Hoffmann VS, Pfirrmann M
Prognostic scoring systems in chronic myeloid leukaemia.
Leukemia. 2025;39:1046-1052.
PubMed Abstract available

TAKAMORI H, Huang YJ, Fukushima H, Yokoyama K, et al
Whole-genome sequencing of myeloproliferative neoplasms revealed dynamic clonal changes in the fibrotic or leukemic transformation and novel FOXP1 mutations in the fibrotic transformation.
Leukemia. 2025;39:1218-1227.
PubMed Abstract available

April 2025

HASAN MK, Widhopf Ii GF, Ghia EM, Kipps TJ, et al
Wnt5a induces ROR1 dependent NF-kappaB activation to enhance MMP-9 expression and invasiveness in chronic lymphocytic leukemia.
Leukemia. 2025 Apr 28. doi: 10.1038/s41375-025-02616.
PubMed Abstract available

MECKLENBRAUCK R, Borchert N, Gabdoulline R, Poll P, et al
Prognostic impact of clonal representation of myelodysplasia-related gene mutations in acute myeloid leukemia.
Leukemia. 2025 Apr 28. doi: 10.1038/s41375-025-02622.
PubMed

KRIZKOVA J, Polivkova V, Laznicka A, Curik N, et al
Somatic mutations and outcomes in chronic myeloid leukemia adolescent and young adults compared to children, adults, and BCR::ABL1-positive acute lymphoblastic leukemia.
Leukemia. 2025 Apr 28. doi: 10.1038/s41375-025-02609.
PubMed Abstract available

GHANI F, Zubair AC
Possible impacts of cosmic radiation on leukemia development during human deep space exploration.
Leukemia. 2025 Apr 24. doi: 10.1038/s41375-025-02624.
PubMed Abstract available

THORVALDSDOTTIR B, Mansouri L, Sutton LA, Nadeu F, et al
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker.
Leukemia. 2025 Apr 24. doi: 10.1038/s41375-025-02615.
PubMed Abstract available

ZHOU T, Short NJ, Jain N, Patel KP, et al
Age-related prognoses of genetic subtypes in B-cell acute lymphoblastic leukemia/lymphoma (B-ALL): insights from a decade of national data.
Leukemia. 2025 Apr 24. doi: 10.1038/s41375-025-02588.
PubMed

GAZEAU N, Beauvais D, Tilmont R, Srour M, et al
Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?
Leukemia. 2025 Apr 24. doi: 10.1038/s41375-025-02605.
PubMed Abstract available

WU JF, Feliciano EJG, Singh A, Tremblay D, et al
National cancer system metrics and leukemia outcomes: an analysis of global data for pediatric and adult patients.
Leukemia. 2025 Apr 23. doi: 10.1038/s41375-025-02598.
PubMed

SHIMA Y, Yamagata K, Kuroki Y, Sasaki K, et al
Loss of NOL10 leads to impaired disease progression of NUP98::DDX10 leukemia.
Leukemia. 2025 Apr 22. doi: 10.1038/s41375-025-02607.
PubMed Abstract available

ASHAYE A, Shi L, Aldoss I, Montesinos P, et al
Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial.
Leukemia. 2025 Apr 16. doi: 10.1038/s41375-025-02608.
PubMed Abstract available

XU Y, Mou J, Wang Y, Zhou W, et al
Correction: Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway.
Leukemia. 2025 Apr 15. doi: 10.1038/s41375-025-02618.
PubMed

NIEDERMAYER A, Stursberg J, Bergmann AK, Zimmermann M, et al
Remission induction in refractory, drug resistant pediatric PICALM::MLLT10+ B-cell acute lymphoblastic leukemia by venetoclax.
Leukemia. 2025 Apr 15. doi: 10.1038/s41375-025-02591.
PubMed

DECHOW A, Timonen S, Ianevski A, Jiang Q, et al
Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemia.
Leukemia. 2025 Apr 15. doi: 10.1038/s41375-025-02577.
PubMed Abstract available

HSU CJ, Schraw JM, Desrosiers TA, Janitz AE, et al
All genetic subtypes of B-cell acute lymphoblastic leukemia exhibit increased incidence rates in children with Down syndrome.
Leukemia. 2025 Apr 11. doi: 10.1038/s41375-025-02602.
PubMed

XING C, Zhang H, Zheng M, Lu Q, et al
Fabp4 is essential for the maintenance of leukemia stem cells while sparing hematopoietic stem cells.
Leukemia. 2025 Apr 10. doi: 10.1038/s41375-025-02568.
PubMed

CORTES JE, Lang F, Rea D, Hochhaus A, et al
Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results.
Leukemia. 2025 Apr 9. doi: 10.1038/s41375-025-02592.
PubMed Abstract available

KAYA F, Bewicke-Copley F, Miettinen JJ, Casado P, et al
DEK::NUP214 acts as an XPO1-dependent transcriptional activator of essential leukemia genes.
Leukemia. 2025 Apr 9. doi: 10.1038/s41375-025-02593.
PubMed Abstract available

HOCHHAUS A, Kim DW, Cortes JE, Sasaki K, et al
Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1(T315I) treated with at least 2 prior TKIs: Phase 1 final results.
Leukemia. 2025 Apr 9. doi: 10.1038/s41375-025-02578.
PubMed Abstract available

PAGANO L, Maschmeyer G, Lamoth F, Blennow O, et al
Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL).
Leukemia. 2025 Apr 9. doi: 10.1038/s41375-025-02586.
PubMed Abstract available

REINHARDT C, Ochsenbein AF
Immune checkpoints regulate acute myeloid leukemia stem cells.
Leukemia. 2025 Apr 2. doi: 10.1038/s41375-025-02566.
PubMed Abstract available

LI R, Wu X, Xue K, Wu S, et al
CircTADA2A stabilizes p53 via interacting with TRIM28 and suppresses the maintenance of FLT3-ITD acute myeloid leukemia.
Leukemia. 2025 Apr 2. doi: 10.1038/s41375-025-02589.
PubMed Abstract available

BUSSOT L, Poulain S, Nudel Ortmans M, Davi F, et al
Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study.
Leukemia. 2025 Apr 1. doi: 10.1038/s41375-025-02555.
PubMed

HUANG J, Xie J, Wang Y, Sheng M, et al
STING mediates increased self-renewal and lineage skewing in DNMT3A-mutated hematopoietic stem/progenitor cells.
Leukemia. 2025;39:929-941.
PubMed Abstract available

SHI C, Tian Z, Yan J, Zhang M, et al
Immunotherapy targeting a leader sequence cathepsin G-derived peptide.
Leukemia. 2025;39:888-898.
PubMed Abstract available

March 2025

AYYADEVARA VSSA, Wertheim G, Gaur S, Chukinas JA, et al
DYRK1A inhibition results in MYC and ERK activation rendering KMT2A-R acute lymphoblastic leukemia cells sensitive to BCL2 inhibition.
Leukemia. 2025 Mar 27. doi: 10.1038/s41375-025-02575.
PubMed Abstract available

CHARLES CANO F, Kloos A, Hebalkar RY, Plenge T, et al
XPO1-dependency of DEK::NUP214 leukemia.
Leukemia. 2025 Mar 27. doi: 10.1038/s41375-025-02570.
PubMed Abstract available

JERKEMAN M, Mellgren K, Sonnevi K, Lisak M, et al
Implementation of standard of care CAR-T-cell treatment for patients with aggressive B-cell lymphoma and acute lymphoblastic leukemia in Sweden.
Leukemia. 2025 Mar 26. doi: 10.1038/s41375-025-02573.
PubMed

STOLTZE U, Junk SV, Byrjalsen A, Cave H, et al
Overt and covert genetic causes of pediatric acute lymphoblastic leukemia.
Leukemia. 2025 Mar 24. doi: 10.1038/s41375-025-02535.
PubMed Abstract available

GEYER J, Opoku KB, Lin J, Ramkissoon L, et al
Real-time genomic characterization of pediatric acute leukemia using adaptive sampling.
Leukemia. 2025 Mar 24. doi: 10.1038/s41375-025-02565.
PubMed Abstract available

COLE FM, Laszlo GS, Lunn-Halbert MC, Kehret AR, et al
Preclinical characterization of the anti-leukemia activity of the CD123 antibody-drug conjugate, pivekimab sunirine (IMGN632).
Leukemia. 2025 Mar 21. doi: 10.1038/s41375-025-02571.
PubMed

ROMPIETTI C, Adamo FM, Sorcini D, De Falco F, et al
Bcor loss promotes Richter transformation of chronic lymphocytic leukemia associated with Notch1 activation in mice.
Leukemia. 2025 Mar 20. doi: 10.1038/s41375-025-02557.
PubMed Abstract available

SHAH BD, Cassaday RD, Park JH, Houot R, et al
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
Leukemia. 2025 Mar 19. doi: 10.1038/s41375-025-02532.
PubMed Abstract available

SPERB N, Maksakova IA, Escano L, Abraham L, et al
The proto-oncogenic miR-106a-363 cluster enhances adverse risk acute myeloid leukemia through mitochondrial activation.
Leukemia. 2025 Mar 17. doi: 10.1038/s41375-025-02558.
PubMed Abstract available

WANG H, Suo S, Li D, Li J, et al
Comparison of subcutaneous injection versus intravenous infusion of cytarabine for induction therapy in adult acute myeloid leukemia.
Leukemia. 2025 Mar 12. doi: 10.1038/s41375-025-02556.
PubMed

KLEPZIG H, Herling M, Pflug N, Braun T, et al
Models for T-large granular lymphocytic leukemia: how to mimic the cellular interplays in malignant autoimmunity.
Leukemia. 2025 Mar 7. doi: 10.1038/s41375-025-02553.
PubMed Abstract available

MILLOT F, Ampatzidou M, Moulik NR, Tewari S, et al
Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations.
Leukemia. 2025 Mar 5. doi: 10.1038/s41375-025-02543.
PubMed Abstract available

LIPTON JH, Rea D
Living, not just surviving, with chronic myeloid leukemia - quality of life to the front of the line.
Leukemia. 2025 Mar 5. doi: 10.1038/s41375-025-02548.
PubMed

BRUNMEIR R, Ying L, Yan J, Hee YT, et al
EZH2 modulates mRNA splicing and exerts part of its oncogenic function through repression of splicing factors in CML.
Leukemia. 2025;39:650-662.
PubMed Abstract available

February 2025

REUVEKAMP T, Ngai LL, den Hartog D, Carbaat-Ham J, et al
CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents.
Leukemia. 2025 Feb 27. doi: 10.1038/s41375-025-02539.
PubMed

DINARDO CD, Jen WY, Takahashi K, Kadia TM, et al
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
Leukemia. 2025 Feb 25. doi: 10.1038/s41375-025-02531.
PubMed Abstract available

GIUDICE V, Selleri C
How fast does leukemia progress?
Leukemia. 2025 Feb 24. doi: 10.1038/s41375-025-02536.
PubMed

MINAMI M, Sakoda T, Kawano G, Kochi Y, et al
Distinct leukemogenic mechanism of acute promyelocytic leukemia based on genomic structure of PML::RARalpha.
Leukemia. 2025 Feb 20. doi: 10.1038/s41375-025-02530.
PubMed Abstract available

HORMANN FM, Rudd SG
Nelarabine in T-cell acute lymphoblastic leukemia: intracellular metabolism and molecular mode-of-action.
Leukemia. 2025 Feb 17. doi: 10.1038/s41375-025-02529.
PubMed Abstract available

ABEDIN SM, Guru Murthy GS, Hamadani M, Michaelis LC, et al
Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia.
Leukemia. 2025 Feb 15. doi: 10.1038/s41375-025-02528.
PubMed Abstract available

OKABE S, Arai Y, Gotoh A
Correspondence to: "Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations", Curik N et al. Leukemia. 2024; 38: 1415-1418.
Leukemia. 2025 Feb 6. doi: 10.1038/s41375-025-02521.
PubMed

SU Y, Han Z, Ji Y, Liu A, et al
Patterns and variations of copy number alterations in acute myeloid leukemia: insights from the LeukAtlas database.
Leukemia. 2025 Feb 2. doi: 10.1038/s41375-025-02514.
PubMed Abstract available

FALINI B, Sorcini D, Perriello VM, Sportoletti P, et al
Functions of the native NPM1 protein and its leukemic mutant.
Leukemia. 2025;39:276-290.
PubMed Abstract available

YANG S, Zhang X, Gale RP, Huang X, et al
Is there really an accelerated phase of chronic myeloid leukaemia at presentation?
Leukemia. 2025;39:391-399.
PubMed Abstract available

CALVO J, Naguibneva I, Kypraios A, Gilain F, et al
High CD44 expression and enhanced E-selectin binding identified as biomarkers of chemoresistant leukemic cells in human T-ALL.
Leukemia. 2025;39:323-336.
PubMed Abstract available

ORTI G, Peczynski C, Boreland W, O'Reilly M, et al
Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study.
Leukemia. 2025;39:431-437.
PubMed Abstract available

January 2025

ABLE M, Kasper MA, Vick B, Schwach J, et al
Effective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates.
Leukemia. 2025 Jan 27. doi: 10.1038/s41375-024-02510.
PubMed Abstract available

LIU J, Kharazmi E, Liang Q, Chen Y, et al
Maternal weight during pregnancy and risk of childhood acute lymphoblastic leukemia in offspring.
Leukemia. 2025 Jan 26. doi: 10.1038/s41375-025-02517.
PubMed Abstract available

TREMBLAY CS, Saw J, Yan F, Boyle JA, et al
Targeting LMO2-induced autocrine FLT3 signaling to overcome chemoresistance in early T-cell precursor acute lymphoblastic leukemia.
Leukemia. 2025 Jan 23. doi: 10.1038/s41375-024-02491.
PubMed Abstract available

LAUWEREINS L, Van Thillo Q, Demeyer S, Mentens N, et al
TLE4 is a repressor of the oncogenic activity of TLX3 in T-cell acute lymphoblastic leukemia.
Leukemia. 2025 Jan 21. doi: 10.1038/s41375-025-02513.
PubMed Abstract available

ADDINSELL HM, Cant R, Hull NJ, Wang YH, et al
Multi-omic analysis of chronic myelomonocytic leukemia monocytes reveals metabolic and immune dysregulation leading to altered macrophage polarization.
Leukemia. 2025 Jan 15. doi: 10.1038/s41375-024-02511.
PubMed

ANABTAWI N, Nicolet D, Alotaibi N, Buelow DR, et al
Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies.
Leukemia. 2025 Jan 13. doi: 10.1038/s41375-024-02498.
PubMed Abstract available

SHAHSWAR R, Gabdoulline R, Krueger K, Wichmann M, et al
A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents.
Leukemia. 2025 Jan 8. doi: 10.1038/s41375-024-02501.
PubMed Abstract available

SHIMOSATO Y, Yamamoto K, Jia Y, Zhang W, et al
NPM1-fusion proteins promote myeloid leukemogenesis through XPO1-dependent HOX activation.
Leukemia. 2025;39:75-86.
PubMed Abstract available

STRULLU M, Caye-Eude A, Robert E, Renard JM, et al
CD36 cell surface expression as a surrogate marker to identify ABL/JAK-class kinase fusions in pediatric BCP-ALL.
Leukemia. 2025;39:64-74.
PubMed Abstract available

JACOBY MA, Duncavage ED, Khanna A, Chang GS, et al
Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response.
Leukemia. 2025;39:166-177.
PubMed Abstract available

LI Z, Fierstein S, Tanaka-Yano M, Frenis K, et al
The epigenetic state of the cell of origin defines mechanisms of leukemogenesis.
Leukemia. 2025;39:87-97.
PubMed Abstract available

December 2024

SHI Z, Li J, Ding J, Zhang Y, et al
ADAR1 is required for acute myeloid leukemia cell survival by modulating post-transcriptional Wnt signaling through impairing miRNA biogenesis.
Leukemia. 2024 Dec 19. doi: 10.1038/s41375-024-02500.
PubMed Abstract available

NABKI J, Al Deeban B, Sium AM, Cosentino C, et al
Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement.
Leukemia. 2024 Dec 17. doi: 10.1038/s41375-024-02499.
PubMed Abstract available

BALESTRA T, Niswander LM, Bagashev A, Loftus JP, et al
Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia.
Leukemia. 2024 Dec 16. doi: 10.1038/s41375-024-02493.
PubMed Abstract available

ORVAIN C, Milano F, Rodriguez-Arboli E, Othus M, et al
Relationship between donor source, pre-transplant measurable residual disease, and outcome after allografting for adults with acute myeloid leukemia.
Leukemia. 2024 Dec 12. doi: 10.1038/s41375-024-02497.
PubMed Abstract available

GERRITSEN M, In 't Hout FEM, Knops R, Mandos BLR, et al
Acute myeloid leukemia associated RUNX1 variants induce aberrant expression of transcription factor TCF4.
Leukemia. 2024 Dec 12. doi: 10.1038/s41375-024-02470.
PubMed

SHIMA H, Tono C, Tanizawa A, Ito M, et al
Growth retardation and adult height in pediatric patients with chronic-phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Leukemia. 2024 Dec 12. doi: 10.1038/s41375-024-02488.
PubMed

ARGYRIADI EA, Steffen IG, Chen-Santel C, Lissat A, et al
Prognostic relevance of treatment deviations in children with relapsed acute lymphoblastic leukemia who were treated in the ALL-REZ BFM 2002 study.
Leukemia. 2024 Dec 11. doi: 10.1038/s41375-024-02474.
PubMed Abstract available

MITSUYUKI S, Shimomura Y, Mizumaki H, Yanada M, et al
Allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with t(16;21)(p11;q22)/FUS::ERG.
Leukemia. 2024 Dec 10. doi: 10.1038/s41375-024-02495.
PubMed

HAMPEL PJ, Rabe KG, Wang Y, Hwang SR, et al
Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy era.
Leukemia. 2024 Dec 10. doi: 10.1038/s41375-024-02492.
PubMed

ARZA-APALATEGI S, Heuts BMH, Bergevoet SM, Meering R, et al
HMX3 is a critical vulnerability in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia.
Leukemia. 2024 Dec 4. doi: 10.1038/s41375-024-02485.
PubMed Abstract available

SHARMAN JP, Egyed M, Jurczak W, Skarbnik A, et al
Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia.
Leukemia. 2024 Dec 3. doi: 10.1038/s41375-024-02487.
PubMed

WALTER W, Nadarajah N, Hutter S, Muller H, et al
Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase.
Leukemia. 2024;38:2644-2652.
PubMed Abstract available

HALILOVIC M, Abdelsalam M, Zabkiewicz J, Lazenby M, et al
Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins.
Leukemia. 2024;38:2561-2572.
PubMed Abstract available

November 2024

LOU J, Zhang Y, Tao J, Jin W, et al
Infection-related pathway activation and vulnerability to arsenic trioxide in acute promyelocytic leukemia with TTMV::RARA.
Leukemia. 2024 Nov 28. doi: 10.1038/s41375-024-02481.
PubMed

HEGDE M, Ahmad MH, Mulet Lazaro R, Sugita M, et al
The co-receptor Neuropilin-1 enhances proliferation in inv(16) acute myeloid leukemia via VEGF signaling.
Leukemia. 2024 Nov 21. doi: 10.1038/s41375-024-02471.
PubMed Abstract available

KAWASHIMA N, Gurnari C, Bravo-Perez C, Kubota Y, et al
Clonal hematopoiesis in large granular lymphocytic leukemia.
Leukemia. 2024 Nov 21. doi: 10.1038/s41375-024-02460.
PubMed Abstract available

DALTVEIT DS, Morgan E, Colombet M, Steliarova-Foucher E, et al
Global patterns of leukemia by subtype, age, and sex in 185 countries in 2022.
Leukemia. 2024 Nov 20. doi: 10.1038/s41375-024-02452.
PubMed Abstract available

KRISHNAMOORTHY V, Daly J, Kim J, Piatnitca L, et al
The glycosyltransferase ST3GAL4 drives immune evasion in acute myeloid leukemia by synthesizing ligands for the glyco-immune checkpoint receptor Siglec-9.
Leukemia. 2024 Nov 17. doi: 10.1038/s41375-024-02454.
PubMed Abstract available

SHAO Q, Wykretowicz J, Hu N, Bedi K, et al
Correction: Aberrant BCAT1 expression augments MTOR activity and accelerates disease progression in chronic lymphocytic leukemia.
Leukemia. 2024 Nov 13. doi: 10.1038/s41375-024-02472.
PubMed

TREMBLAY D, Csizmar C, DiNardo CD, Ball S, et al
Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study.
Leukemia. 2024 Nov 12. doi: 10.1038/s41375-024-02466.
PubMed

BOUEYA IL, Sandhow L, Albuquerque JRP, Znaidi R, et al
Endothelial heterogeneity in bone marrow: insights across development, adult life and leukemia.
Leukemia. 2024 Nov 11. doi: 10.1038/s41375-024-02453.
PubMed Abstract available

LI X, Zheng M, Ma S, Nie F, et al
YTHDC1 is a therapeutic target for B-cell acute lymphoblastic leukemia by attenuating DNA damage response through the KMT2C-H3K4me1/me3 epigenetic axis.
Leukemia. 2024 Nov 5. doi: 10.1038/s41375-024-02451.
PubMed Abstract available

EL CHAER F, Perissinotti AJ, Loghavi S, Zeidan AM, et al
Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?
Leukemia. 2024 Nov 5. doi: 10.1038/s41375-024-02458.
PubMed Abstract available

SHAO X, Yokomori R, Ong JZL, Shen H, et al
Transcriptional regulatory program controlled by MYB in T-cell acute lymphoblastic leukemia.
Leukemia. 2024 Nov 2. doi: 10.1038/s41375-024-02455.
PubMed Abstract available

INNES AJ, Hayden C, Orovboni V, Claudiani S, et al
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy.
Leukemia. 2024;38:2443-2455.
PubMed Abstract available

October 2024

SHIMONI A, Peczynski C, Labopin M, Kulagin A, et al
Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia.
Leukemia. 2024 Oct 31. doi: 10.1038/s41375-024-02445.
PubMed Abstract available

SAFA-TAHAR-HENNI S, Paez Martinez K, Gress V, Esparza N, et al
Comparative small molecule screening of primary human acute leukemias, engineered human leukemia and leukemia cell lines.
Leukemia. 2024 Oct 29. doi: 10.1038/s41375-024-02400.
PubMed Abstract available

SHAO Q, Wykretowicz J, Hu N, Bedi K, et al
Aberrant BCAT1 expression augments MTOR activity and accelerates disease progression in chronic lymphocytic leukemia.
Leukemia. 2024 Oct 25. doi: 10.1038/s41375-024-02448.
PubMed Abstract available

NARDI F, Del Prete R, Drago R, Di Rita A, et al
Apoliprotein E-mediated ferroptosis controls cellular proliferation in chronic lymphocytic leukemia.
Leukemia. 2024 Oct 23. doi: 10.1038/s41375-024-02442.
PubMed Abstract available

YU M, Nah GSS, Krishnan V, Sulaimi FNB, et al
The BIM deletion polymorphism potentiates the survival of leukemia stem and progenitor cells and impairs response to targeted therapies.
Leukemia. 2024 Oct 22. doi: 10.1038/s41375-024-02418.
PubMed Abstract available

YANG C, Hu Y, Gao L, Li Z, et al
Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia.
Leukemia. 2024 Oct 15. doi: 10.1038/s41375-024-02437.
PubMed Abstract available

TETTERO JM, Cloos J, Bullinger L
Acute myeloid leukemia: does sex matter?
Leukemia. 2024 Oct 14. doi: 10.1038/s41375-024-02435.
PubMed

YAMAMOTO Y, Iba S, Inaguma Y, Okamoto A, et al
ELC52: a novel megakaryocytic leukemia cell line with a CALR type 1 mutation.
Leukemia. 2024 Oct 8. doi: 10.1038/s41375-024-02434.
PubMed

SUNAMI Y, Yoshino S, Yamazaki Y, Iwamoto T, et al
Rapid increase of C/EBPalpha p42 induces growth arrest of acute myeloid leukemia (AML) cells by Cop1 deletion in Trib1-expressing AML.
Leukemia. 2024 Oct 4. doi: 10.1038/s41375-024-02430.
PubMed Abstract available

ZHANG N, Wen D, Wang T, Deng J, et al
Disparities in incidence and mortality of pediatric acute lymphoblastic leukemia across countries with different incomes.
Leukemia. 2024 Oct 4. doi: 10.1038/s41375-024-02433.
PubMed

GODA C, Kulkarni R, Bustos Y, Li W, et al
Cellular taxonomy of the preleukemic bone marrow niche of acute myeloid leukemia.
Leukemia. 2024 Oct 2. doi: 10.1038/s41375-024-02415.
PubMed Abstract available

KAZERANI M, Marcinek A, Philipp N, Brauchle B, et al
Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell engager-mediated function of bone marrow T cells at remission compared to initial diagnosis and relapse.
Leukemia. 2024;38:2270-2275.
PubMed

LEE YJ, Lee SY, Kim S, Kim SH, et al
REXO5 promotes genomic integrity through regulating R-loop using its exonuclease activity.
Leukemia. 2024;38:2150-2161.
PubMed Abstract available

GALE RP, Jiang Q, Apperley JF, Hochhaus A, et al
Is there really an accelerated phase of chronic myeloid leukaemia?
Leukemia. 2024;38:2085-2086.
PubMed

September 2024

PATEL SA
Managing the unmanageable: evidence-driven approaches to real-world patient prototypes of TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia.
Leukemia. 2024 Sep 30. doi: 10.1038/s41375-024-02417.
PubMed Abstract available

SAKAMOTO KM
Can PROTACs cure Leukemia?
Leukemia. 2024 Sep 26. doi: 10.1038/s41375-024-02427.
PubMed

RAVANDI F, Senapati J, Jain N, Short NJ, et al
Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma.
Leukemia. 2024 Sep 25. doi: 10.1038/s41375-024-02414.
PubMed Abstract available

HUELSE JM, Bhasin SS, Jacobsen KM, Yim J, et al
MERTK inhibition selectively activates a DC - T-cell axis to provide anti-leukemia immunity.
Leukemia. 2024 Sep 25. doi: 10.1038/s41375-024-02408.
PubMed Abstract available

VOLTA L, Myburgh R, Pellegrino C, Koch C, et al
Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells.
Leukemia. 2024 Sep 18. doi: 10.1038/s41375-024-02409.
PubMed Abstract available

CHELYSHEVA E, Apperley J, Turkina A, Yassin MA, et al
Correction: Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry.
Leukemia. 2024 Sep 17. doi: 10.1038/s41375-024-02412.
PubMed

ZHANG W, Yamamoto K, Chang YH, Yabushita T, et al
HDAC7 is a potential therapeutic target in acute erythroid leukemia.
Leukemia. 2024 Sep 15. doi: 10.1038/s41375-024-02394.
PubMed Abstract available

LIU B, Zhang X, Zhou Y, Liu H, et al
USP4 regulates ribosome biogenesis and protein synthesis for hematopoietic stem cell regeneration and leukemia progression.
Leukemia. 2024 Sep 12. doi: 10.1038/s41375-024-02338.
PubMed Abstract available

RABIAN F, Chevret S, Gruson B, Thepot S, et al
Eltrombopag in chronic myelomonocytic leukemia with severe thrombocytopenia. A Groupe Francophone des Myelodysplasies (GFM) study.
Leukemia. 2024 Sep 12. doi: 10.1038/s41375-024-02402.
PubMed

KORBECKI J, Bosiacki M, Kupnicka P, Barczak K, et al
CXCR4 as a therapeutic target in acute myeloid leukemia.
Leukemia. 2024 Sep 11. doi: 10.1038/s41375-024-02326.
PubMed Abstract available

HAGERSTRAND D, Oder B, Cortese D, Qu Y, et al
The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia.
Leukemia. 2024 Sep 11. doi: 10.1038/s41375-024-02379.
PubMed Abstract available

RHEINGOLD SR, Bhojwani D, Ji L, Xu X, et al
Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children's Oncology Group study.
Leukemia. 2024 Sep 11. doi: 10.1038/s41375-024-02395.
PubMed Abstract available

STUTTERHEIM J, van der Waarden R, de Groot-Kruseman HA, Sonneveld E, et al
Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia?
Leukemia. 2024 Sep 10. doi: 10.1038/s41375-024-02386.
PubMed Abstract available

LIU T, Xu K, Pardeshi A, Myint SS, et al
Early-life tobacco exposure is causally implicated in aberrant RAG-mediated recombination in childhood acute lymphoblastic leukemia.
Leukemia. 2024 Sep 9. doi: 10.1038/s41375-024-02407.
PubMed

BOUCHER A, Murray J, Rao S
Cohesin mutations in acute myeloid leukemia.
Leukemia. 2024 Sep 9. doi: 10.1038/s41375-024-02406.
PubMed Abstract available

WANG J, Jiang B, Li J, Liu L, et al
Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.
Leukemia. 2024 Sep 5. doi: 10.1038/s41375-024-02382.
PubMed Abstract available

VAN DER HAM CG, Suurenbroek LC, Kleisman MM, Antic Z, et al
Mutational mechanisms in multiply relapsed pediatric acute lymphoblastic leukemia.
Leukemia. 2024 Sep 4. doi: 10.1038/s41375-024-02403.
PubMed Abstract available

JABBOUR E, Apperley J, Cortes J, Rea D, et al
Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
Leukemia. 2024 Sep 2. doi: 10.1038/s41375-024-02385.
PubMed

TOMA MM, Skorski T
Star wars against leukemia: attacking the clones.
Leukemia. 2024 Sep 2. doi: 10.1038/s41375-024-02369.
PubMed Abstract available

CRUZ-RODRIGUEZ N, Tang H, Bateman B, Tang W, et al
BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of Ph(+) leukemias?
Leukemia. 2024;38:1885-1893.
PubMed Abstract available

LEYTE-VIDAL A, DeFilippis R, Outhwaite IR, Kwan I, et al
Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib.
Leukemia. 2024;38:2046-2050.
PubMed

PIEMONTESE S, Labopin M, Choi G, Broers AEC, et al
Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide.
Leukemia. 2024;38:2016-2022.
PubMed Abstract available

JANN JC, Hergott CB, Winkler M, Liu Y, et al
Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes.
Leukemia. 2024;38:1992-2002.
PubMed Abstract available

WANG J, Zhang Y, Li L, Wang L, et al
Nudt15-mediated inflammatory signaling contributes to divergent outcomes in leukemogenesis and hematopoiesis.
Leukemia. 2024;38:1958-1970.
PubMed Abstract available

KEWAN T, Bahaj WS, Gurnari C, Ogbue OD, et al
Clinical and molecular characteristics of extramedullary acute myeloid leukemias.
Leukemia. 2024;38:2032-2036.
PubMed

AL AMRI R, Baloda V, Monaghan SA, Rosado FG, et al
Validation of independent prognostic significance of blast count in a large cohort of MDS patients.
Leukemia. 2024;38:2064-2067.
PubMed

SPERK A, Gabriel A, Koch D, Augsburger A, et al
FBXL6 is a vulnerability in AML and unmasks proteolytic cleavage as a major experimental pitfall in myeloid cells.
Leukemia. 2024;38:2027-2031.
PubMed

JALNAPURKAR SS, Pawar AS, George SS, Antony C, et al
PHF6 suppresses self-renewal of leukemic stem cells in AML.
Leukemia. 2024;38:1938-1948.
PubMed Abstract available

MOORMAN AV, Enshaei A, Murdy D, Joy M, et al
Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction.
Leukemia. 2024;38:2023-2026.
PubMed

HERNANDEZ-SANCHEZ A, Gonzalez T, Sobas M, Strang E, et al
Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study.
Leukemia. 2024;38:1929-1937.
PubMed Abstract available

LESKE IB, Hantschel O
The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib.
Leukemia. 2024;38:2041-2045.
PubMed

August 2024

DERIGS P, Schubert ML, Dreger P, Schmitt A, et al
Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study.
Leukemia. 2024 Aug 27. doi: 10.1038/s41375-024-02392.
PubMed Abstract available

PASTORCZAK A, Urbanska Z, Styka B, Miarka-Walczyk K, et al
Genetic hallmarks and clinical implications of chromothripsis in childhood T-cell acute lymphoblastic leukemia.
Leukemia. 2024 Aug 27. doi: 10.1038/s41375-024-02370.
PubMed Abstract available

DEMBITZ V, Lawson H, Burt R, Natani S, et al
Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation.
Leukemia. 2024 Aug 26. doi: 10.1038/s41375-024-02390.
PubMed Abstract available

KOEDIJK JB, van der Werf I, Penter L, Vermeulen MA, et al
A multidimensional analysis reveals distinct immune phenotypes and the composition of immune aggregates in pediatric acute myeloid leukemia.
Leukemia. 2024 Aug 26. doi: 10.1038/s41375-024-02381.
PubMed Abstract available

CUGLIEVAN B, Kantarjian H, Rubnitz JE, Cooper TM, et al
Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community.
Leukemia. 2024 Aug 23. doi: 10.1038/s41375-024-02368.
PubMed Abstract available

SUN Y, Wu Y, Pang G, Huang J, et al
STING is crucial for the survival of RUNX1::RUNX1T1 leukemia cells.
Leukemia. 2024 Aug 23. doi: 10.1038/s41375-024-02383.
PubMed Abstract available

RODRIGUEZ-ARBOLI E, Othus M, Freeman SD, Buccisano F, et al
Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML).
Leukemia. 2024 Aug 21. doi: 10.1038/s41375-024-02378.
PubMed

BOUTZEN H, Murison A, Oriecuia A, Bansal S, et al
Identification of leukemia stem cell subsets with distinct transcriptional, epigenetic and functional properties.
Leukemia. 2024 Aug 21. doi: 10.1038/s41375-024-02358.
PubMed Abstract available

GAMBACORTI-PASSERINI C, Brummendorf TH, Abruzzese E, Kelly KR, et al
Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial.
Leukemia. 2024 Aug 20. doi: 10.1038/s41375-024-02372.
PubMed Abstract available

TISSINO E, Gaglio A, Nicolo A, Pozzo F, et al
The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands.
Leukemia. 2024 Aug 14. doi: 10.1038/s41375-024-02376.
PubMed Abstract available

ATAR D, Ruoff L, Mast AS, Krost S, et al
Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia.
Leukemia. 2024 Aug 3. doi: 10.1038/s41375-024-02351.
PubMed Abstract available

CHATAIN N, Baumeister J, Szymanski de Toledo MA, Wong DWL, et al
Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells.
Leukemia. 2024;38:1825-1830.
PubMed Abstract available

HOFERKOVA E, Seda V, Kadakova S, Verner J, et al
Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugs.
Leukemia. 2024;38:1699-1711.
PubMed Abstract available

BOUSQUETS-MUNOZ P, Molina O, Varela I, Alvarez-Eguiluz A, et al
Backtracking NOM1::ETV6 fusion to neonatal pathogenesis of t(7;12) (q36;p13) infant AML.
Leukemia. 2024;38:1808-1812.
PubMed

FONTANA D, Malighetti F, Villa M, Zambon A, et al
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1.
Leukemia. 2024;38:1843-1847.
PubMed

FARHAT M, Croft W, Parry HM, Verma K, et al
PD-1 expression contributes to functional impairment of NK cells in patients with B-CLL.
Leukemia. 2024;38:1813-1817.
PubMed

GALE RP, Phillips GL, Lazarus HM
A modest proposal to the transplant publik to prevent harm to people with acute myeloid leukaemia in 1st complete remission cured by chemotherapy.
Leukemia. 2024;38:1663-1666.
PubMed

July 2024

WONG RL, Choi MY, Wang HY, Kipps TJ, et al
Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia.
Leukemia. 2024 Jul 24. doi: 10.1038/s41375-024-02317.
PubMed Abstract available

KONOPLEVA M, Milella M, Ruvolo P, Watts JC, et al
Retraction Note: MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
Leukemia. 2024 Jul 18. doi: 10.1038/s41375-024-02339.
PubMed

ORVAIN C, Bertoli S, Peterlin P, Desbrosses Y, et al
Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study.
Leukemia. 2024 Jul 17. doi: 10.1038/s41375-024-02335.
PubMed Abstract available

TERASAKI T, Semba Y, Sasaki K, Imanaga H, et al
The RNA helicases DDX19A/B modulate selinexor sensitivity by regulating MCL1 mRNA nuclear export in leukemia cells.
Leukemia. 2024 Jul 11. doi: 10.1038/s41375-024-02343.
PubMed Abstract available

EFFICACE F, Mahon FX, Richter J, Piciocchi A, et al
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial.
Leukemia. 2024 Jul 10. doi: 10.1038/s41375-024-02341.
PubMed Abstract available

OGBUE O, Kewan T, Bravo-Perez C, Unlu S, et al
Hemolytic versus malproductive anemia in large granular lymphocytic leukemia.
Leukemia. 2024 Jul 9. doi: 10.1038/s41375-024-02323.
PubMed

KIM H, Tan TK, Lee DZY, Huang XZ, et al
Oncogenic dependency on SWI/SNF chromatin remodeling factors in T-cell acute lymphoblastic leukemia.
Leukemia. 2024 Jul 5. doi: 10.1038/s41375-024-02331.
PubMed Abstract available

ERNST P, Rinke J, Franke GN, Dicker F, et al
Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation.
Leukemia. 2024 Jul 4. doi: 10.1038/s41375-024-02327.
PubMed

DIEDRICH JD, Dong Q, Ferguson DC, Bergeron BP, et al
Correction: Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks.
Leukemia. 2024 Jul 3. doi: 10.1038/s41375-024-02291.
PubMed

YAMAMOTO Y, Watanabe T, Ureshino H, Kurahashi Y, et al
DNA demethylating agents for chemoprevention of oncovirus-associated leukemogenesis.
Leukemia. 2024;38:1613-1616.
PubMed

SHAO Y, Kay NE, Gale RP, Liang Y, et al
Challenges in analyzing clinical trials testing Bruton tyrosine-kinase-inhibitora in chronic lymphocytic leukaemia.
Leukemia. 2024;38:1469-1473.
PubMed

SCOTT S, Devonshire A, Dillon R, Thiede C, et al
Recommendations from the AML molecular MRD expert advisory board.
Leukemia. 2024;38:1638-1641.
PubMed

MASLAH N, Rety S, Bonnamy M, Aguinaga L, et al
Niclosamide combined to Azacitidine to target TP53-mutated MDS/AML cells.
Leukemia. 2024;38:1630-1633.
PubMed

GROSS G, Alkadieri S, Meir A, Itzhaki O, et al
Improved CAR-T cell activity associated with increased mitochondrial function primed by galactose.
Leukemia. 2024;38:1534-1540.
PubMed Abstract available

SHIMONY S, Garcia JS, Keating J, Chen EC, et al
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients.
Leukemia. 2024;38:1494-1500.
PubMed Abstract available

KOVECSES O, Mercier FE, McKeague M
Nucleic acid therapeutics as differentiation agents for myeloid leukemias.
Leukemia. 2024;38:1441-1454.
PubMed Abstract available

June 2024

YUN H, Zoller J, Zhou F, Rohde C, et al
The landscape of RNA-chromatin interaction reveals small non-coding RNAs as essential mediators of leukemia maintenance.
Leukemia. 2024 Jun 28. doi: 10.1038/s41375-024-02322.
PubMed Abstract available

GALE RP, Hochhaus A
Correction: To Mars and beyond. Space exploration and space medicine in Leukemia.
Leukemia. 2024 Jun 25. doi: 10.1038/s41375-024-02324.
PubMed

POZZO F, Forestieri G, Vit F, Ianna G, et al
Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.
Leukemia. 2024 Jun 24. doi: 10.1038/s41375-024-02301.
PubMed Abstract available

YANAGIYA R, Miyatake Y, Watanabe N, Shimizu T, et al
Amino acid influx via LAT1 regulates iron demand and sensitivity to PPMX-T003 of aggressive natural killer cell leukemia.
Leukemia. 2024 Jun 24. doi: 10.1038/s41375-024-02296.
PubMed Abstract available

PHILIPPE C, Jaud M, Feral K, Gay A, et al
Pivotal role of the endoplasmic reticulum stress-related XBP1s/miR-22/SIRT1 axis in acute myeloid leukemia apoptosis and response to chemotherapy.
Leukemia. 2024 Jun 22. doi: 10.1038/s41375-024-02321.
PubMed Abstract available

ABOU DALLE I, Moukalled N, El Cheikh J, Mohty M, et al
Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently asked questions.
Leukemia. 2024 Jun 20. doi: 10.1038/s41375-024-02319.
PubMed Abstract available

MCCARTHY N, Gui G, Dumezy F, Roumier C, et al
Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillance.
Leukemia. 2024 Jun 18. doi: 10.1038/s41375-024-02300.
PubMed Abstract available

MIAO H, Chen D, Ropa J, Purohit T, et al
Combination of menin and kinase inhibitors as an effective treatment for leukemia with NUP98 translocations.
Leukemia. 2024 Jun 18. doi: 10.1038/s41375-024-02312.
PubMed Abstract available

SALA-TORRA O, Beppu L, Wu Q, Welch E, et al
Point-of-care BCR::ABL1 transcript monitoring using capillary dried blood in chronic myeloid leukemia patients.
Leukemia. 2024 Jun 15. doi: 10.1038/s41375-024-02285.
PubMed

GREVER M, Andritsos L, Anghelina M, Arons E, et al
Hairy cell leukemia variant and WHO classification correspondence Re: 5(th) edition WHO classification haematolymphoid tumors: lymphoid neoplasms.
Leukemia. 2024 Jun 8. doi: 10.1038/s41375-024-02280.
PubMed

OSTERGAARD A, Fiocco M, de Groot-Kruseman H, Moorman AV, et al
ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?
Leukemia. 2024 Jun 6. doi: 10.1038/s41375-024-02287.
PubMed Abstract available

ZHANG MY, Othus M, McMillen K, Erba HP, et al
Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203.
Leukemia. 2024 Jun 3. doi: 10.1038/s41375-024-02288.
PubMed Abstract available

VAN DER VELDEN VHJ, Dombrink I, Alten J, Cazzaniga G, et al
Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines.
Leukemia. 2024;38:1315-1322.
PubMed Abstract available

SAYITOGLU EC, Luca BA, Boss AP, Thomas BC, et al
AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML.
Leukemia. 2024;38:1246-1255.
PubMed Abstract available

YANG M, Ma Z, Wang C, Agca MC, et al
Cre recombinase promotes leukemogenesis in the presence of both homozygous and heterozygous FLT3-ITD.
Leukemia. 2024;38:1437-1439.
PubMed

LU W, Lyu H, Xiao X, Bai X, et al
Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation.
Leukemia. 2024;38:1419-1422.
PubMed

VAN SPRONSEN MF, Van Gassen S, Duetz C, Westers TM, et al
Myelodysplastic neoplasms dissected into indolent, leukaemic and unfavourable subtypes by computational clustering of haematopoietic stem and progenitor cells.
Leukemia. 2024;38:1365-1377.
PubMed Abstract available

PERZOLLI A, Koedijk JB, Zwaan CM, Heidenreich O, et al
Targeting the innate immune system in pediatric and adult AML.
Leukemia. 2024;38:1191-1201.
PubMed Abstract available

May 2024

ZHU R, Shirley CM, Chu SH, Li L, et al
Inhibition of NOTCH4 sensitizes FLT3/ITD acute myeloid leukemia cells to FLT3 tyrosine kinase inhibition.
Leukemia. 2024 May 29. doi: 10.1038/s41375-024-02292.
PubMed Abstract available

GALE RP, Hochhaus A
To Mars and beyond. Space exploration and space medicine in Leukemia.
Leukemia. 2024 May 22. doi: 10.1038/s41375-024-02286.
PubMed

RUJKIJYANONT P, Inaba H
Diagnostic and treatment strategies for pediatric acute lymphoblastic leukemia in low- and middle-income countries.
Leukemia. 2024 May 18. doi: 10.1038/s41375-024-02277.
PubMed Abstract available

CORTES JE, Sasaki K, Kim DW, Hughes TP, et al
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after >/=1 prior tyrosine kinase inhibitor: 2-year follow-up results.
Leukemia. 2024 May 16. doi: 10.1038/s41375-024-02278.
PubMed Abstract available

MALCIKOVA J, Pavlova S, Baliakas P, Chatzikonstantinou T, et al
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update.
Leukemia. 2024 May 16. doi: 10.1038/s41375-024-02267.
PubMed Abstract available

NEUMANN M, Beder T, Bastian L, Hanzelmann S, et al
Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols.
Leukemia. 2024 May 14. doi: 10.1038/s41375-024-02264.
PubMed Abstract available

KARAMI A, Skorski T
DNA damage response genes as biomarkers of therapeutic outcomes in acute myeloid leukemia patients.
Leukemia. 2024 May 11. doi: 10.1038/s41375-024-02269.
PubMed

AWADA H, Durmaz A, Kewan T, Ullah F, et al
Context-dependent role of trisomy 6 in myelodysplastic neoplasms and acute myeloid leukemia: a multi-omics analysis.
Leukemia. 2024 May 11. doi: 10.1038/s41375-024-02268.
PubMed

MORII M, Kubota S, Iimori M, Yokomizo-Nakano T, et al
TIF1beta activates leukemic transcriptional program in HSCs and promotes BCR::ABL1-induced myeloid leukemia.
Leukemia. 2024 May 11. doi: 10.1038/s41375-024-02276.
PubMed Abstract available

O'CONNOR KW, Kishimoto K, Kuzma IO, Wagner KP, et al
The role of quiescent thymic progenitors in TAL/LMO2-induced T-ALL chemotolerance.
Leukemia. 2024;38:951-962.
PubMed Abstract available

SRINIVASAN S, Keerthivasagam S
Mitigating immortal-time bias: exploring osteonecrosis and survival in pediatric ALL - AALL0232 trial insights.
Leukemia. 2024;38:1187-1188.
PubMed

SCHULTZ LM, Jeyakumar N, Kramer AM, Sahaf B, et al
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.
Leukemia. 2024;38:963-968.
PubMed Abstract available

WONG JC, Weinfurtner KM, Westover T, Kim J, et al
5G2 mutant mice model loss of a commonly deleted segment of chromosome 7q22 in myeloid malignancies.
Leukemia. 2024;38:1182-1186.
PubMed Abstract available

YI W, Zhang J, Huang Y, Zhan Q, et al
Ferritin-mediated mitochondrial iron homeostasis is essential for the survival of hematopoietic stem cells and leukemic stem cells.
Leukemia. 2024;38:1003-1018.
PubMed Abstract available

April 2024

GUO J, Buettner R, Du L, Li Z, et al
8-Cl-Ado and 8-NH(2)-Ado synergize with venetoclax to target the methionine-MAT2A-SAM axis in acute myeloid leukemia.
Leukemia. 2024 Apr 20. doi: 10.1038/s41375-024-02222.
PubMed Abstract available

IYODA S, Yoshida K, Shoji K, Ito N, et al
KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia.
Leukemia. 2024 Apr 18. doi: 10.1038/s41375-024-02244.
PubMed

NORONHA N, Durette C, Cahuzac M, E Silva B, et al
Autophagy degrades immunogenic endogenous retroelements induced by 5-azacytidine in acute myeloid leukemia.
Leukemia. 2024 Apr 16. doi: 10.1038/s41375-024-02250.
PubMed Abstract available

CURIK N, Laznicka A, Polivkova V, Krizkova J, et al
Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations.
Leukemia. 2024 Apr 13. doi: 10.1038/s41375-024-02248.
PubMed

MATSUI S, Ri C, Bolanos LC, Choi K, et al
Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression.
Leukemia. 2024 Apr 12. doi: 10.1038/s41375-024-02245.
PubMed Abstract available

BELL HL, Blair HJ, Jepson Gosling SJ, Galler M, et al
Combination p53 activation and BCL-x(L)/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.
Leukemia. 2024 Apr 10. doi: 10.1038/s41375-024-02241.
PubMed Abstract available

FRUCHTMAN H, Avigan ZM, Waksal JA, Brennan N, et al
Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia.
Leukemia. 2024 Apr 10. doi: 10.1038/s41375-024-02246.
PubMed Abstract available

BORDINI J, Lenzi C, Frenquelli M, Morabito A, et al
IkappaBepsilon deficiency accelerates disease development in chronic lymphocytic leukemia.
Leukemia. 2024 Apr 4. doi: 10.1038/s41375-024-02236.
PubMed Abstract available

MCLORNAN DP, Czerw T, Damaj G, Ethell M, et al
Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee.
Leukemia. 2024;38:699-711.
PubMed Abstract available

LUBKE J, Christen D, Schwaab J, Kaiser A, et al
Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries.
Leukemia. 2024;38:810-821.
PubMed Abstract available

SHIMONY S, Bewersdorf JP, Shallis RM, Liu Y, et al
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
Leukemia. 2024;38:762-768.
PubMed Abstract available

SEBERT M, Freiman L, Chaffaut C, Guerci A, et al
Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens.
Leukemia. 2024;38:918-922.
PubMed

SEVERENS JF, Karakaslar EO, van der Reijden BA, Sanchez-Lopez E, et al
Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses.
Leukemia. 2024;38:751-761.
PubMed Abstract available

March 2024

JASSINSKAJA M, Ghosh S, Watral J, Davoudi M, et al
A complex interplay of intra- and extracellular factors regulates the outcome of fetal- and adult-derived MLL-rearranged leukemia.
Leukemia. 2024 Mar 30. doi: 10.1038/s41375-024-02235.
PubMed Abstract available

BRIOLI A, Lomaia E, Fabisch C, Sacha T, et al
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.
Leukemia. 2024 Mar 28. doi: 10.1038/s41375-024-02204.
PubMed Abstract available

DE CAMARGO MAGALHAES ES, Hubner SE, Brown BD, Qiu Y, et al
Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy.
Leukemia. 2024 Mar 26. doi: 10.1038/s41375-024-02208.
PubMed Abstract available

KANTARJIAN H, Branford S, Breccia M, Cortes J, et al
Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?
Leukemia. 2024 Mar 26. doi: 10.1038/s41375-024-02229.
PubMed

BURMEISTER T, Stroh AS, Kehden B, Trautmann H, et al
Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia.
Leukemia. 2024 Mar 22. doi: 10.1038/s41375-024-02209.
PubMed

FARROKHI A, Atre T, Rever J, Fidanza M, et al
The Emu-Ret mouse is a novel model of hyperdiploid B-cell acute lymphoblastic leukemia.
Leukemia. 2024 Mar 22. doi: 10.1038/s41375-024-02221.
PubMed Abstract available

BONATO A, Chakraborty S, Bomben R, Canarutto G, et al
NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia.
Leukemia. 2024 Mar 15. doi: 10.1038/s41375-024-02224.
PubMed Abstract available

ZACKOVA D, Semerad L, Faber E, Klamova H, et al
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF.
Leukemia. 2024 Mar 12. doi: 10.1038/s41375-024-02215.
PubMed

SCHWEDE M, Jahn K, Kuipers J, Miles LA, et al
Mutation order in acute myeloid leukemia identifies uncommon patterns of evolution and illuminates phenotypic heterogeneity.
Leukemia. 2024 Mar 11. doi: 10.1038/s41375-024-02211.
PubMed Abstract available

AKIYAMA H, Zhao R, Ostermann LB, Li Z, et al
Correction: Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia.
Leukemia. 2024 Mar 8. doi: 10.1038/s41375-024-02202.
PubMed

THOMAS ME 3RD, Qi W, Walsh MP, Ma J, et al
Functional characterization of cooperating MGA mutations in RUNX1::RUNX1T1 acute myeloid leukemia.
Leukemia. 2024 Mar 7. doi: 10.1038/s41375-024-02193.
PubMed Abstract available

PERUSINI MA, Andrews C, Eshetu AG, Gupta V, et al
Asparaginase completion among adults including older patients with acute lymphoblastic leukemia treated with a modified DFCI protocol.
Leukemia. 2024 Mar 2. doi: 10.1038/s41375-024-02201.
PubMed

MA J, Liu YC, Voss RK, Ma J, et al
Genomic and global gene expression profiling in pediatric and young adult acute leukemia with PICALM::MLLT10 Fusion.
Leukemia. 2024 Mar 1. doi: 10.1038/s41375-024-02194.
PubMed Abstract available

CHEN CC, Silberman RE, Ma D, Perry JA, et al
Inherent genome instability underlies trisomy 21-associated myeloid malignancies.
Leukemia. 2024;38:521-529.
PubMed Abstract available

SANZ-ORTEGA L, Andersson A, Carlsten M
Harnessing upregulated E-selectin while enhancing SDF-1alpha sensing redirects infused NK cells to the AML-perturbed bone marrow.
Leukemia. 2024;38:579-589.
PubMed Abstract available

PARRIOTT G, Hegermiller E, Morman RE, Frank C, et al
Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T-ALL.
Leukemia. 2024;38:491-501.
PubMed Abstract available

SPINELLA JF, Chagraoui J, Moison C, Lavallee VP, et al
DELE1 haploinsufficiency causes resistance to mitochondrial stress-induced apoptosis in monosomy 5/del(5q) AML.
Leukemia. 2024;38:530-537.
PubMed Abstract available

BIRDWELL CE, Fiskus W, Kadia TM, Mill CP, et al
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.
Leukemia. 2024;38:545-556.
PubMed Abstract available

February 2024

CLAUDIANI S, Chughtai F, Khan A, Hayden C, et al
Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance.
Leukemia. 2024 Feb 29. doi: 10.1038/s41375-024-02187.
PubMed Abstract available

YANG X, Liu J, Liu W, Wu H, et al
circFAM193B interaction with PRMT6 regulates AML leukemia stem cells chemoresistance through altering the oxidative metabolism and lipid peroxidation.
Leukemia. 2024 Feb 29. doi: 10.1038/s41375-024-02189.
PubMed Abstract available

FLYGT H, Soderlund S, Richter J, Saussele S, et al
Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
Leukemia. 2024 Feb 28. doi: 10.1038/s41375-024-02184.
PubMed

MONTALBAN-BRAVO G, Rodriguez-Sevilla JJ, Swanson DM, Kanagal-Shamanna R, et al
Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia.
Leukemia. 2024 Feb 28. doi: 10.1038/s41375-024-02190.
PubMed

JUNK SV, Forster A, Schmidt G, Zimmermann M, et al
Germline variants in patients developing second malignant neoplasms after therapy for pediatric acute lymphoblastic leukemia-a case-control study.
Leukemia. 2024 Feb 27. doi: 10.1038/s41375-024-02173.
PubMed

CHELYSHEVA E, Apperley J, Turkina A, Yassin MA, et al
Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry.
Leukemia. 2024 Feb 23. doi: 10.1038/s41375-024-02183.
PubMed Abstract available

OLIVIERI DJ, Othus M, Orvain C, Rodriguez-Arboli E, et al
Impact of socioeconomic disparities on outcomes in adults undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukemia.
Leukemia. 2024 Feb 22. doi: 10.1038/s41375-024-02172.
PubMed Abstract available

AVENARIUS MR, Huang Y, Kittai AS, Bhat SA, et al
Comparison of karyotype scoring guidelines for evaluating karyotype complexity in chronic lymphocytic leukemia.
Leukemia. 2024 Feb 19. doi: 10.1038/s41375-024-02177.
PubMed

CHATZIKONSTANTINOU T, Agathangelidis A, Chatzidimitriou A, Tresoldi C, et al
Updates of the ERIC recommendations on how to report the results from immunoglobulin heavy variable gene analysis in chronic lymphocytic leukemia.
Leukemia. 2024 Feb 16. doi: 10.1038/s41375-024-02163.
PubMed

LIN S, Schneider C, Su AH, Alexe G, et al
The UBE2J2/UBE2K-MARCH5 ubiquitination machinery regulates apoptosis in response to venetoclax in acute myeloid leukemia.
Leukemia. 2024 Feb 16. doi: 10.1038/s41375-024-02178.
PubMed

DELROCCO NJ, Loh ML, Borowitz MJ, Gupta S, et al
Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report.
Leukemia. 2024 Feb 15. doi: 10.1038/s41375-024-02166.
PubMed Abstract available

LI Y, Mendoza-Castrejon J, Patel RM, Casey EB, et al
LIN28B promotes differentiation of fully transformed AML cells but is dispensable for fetal leukemia suppression.
Leukemia. 2024 Feb 6. doi: 10.1038/s41375-024-02167.
PubMed

FRANKHOUSER DE, Rockne RC, Uechi L, Zhao D, et al
State-transition modeling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia.
Leukemia. 2024 Feb 2. doi: 10.1038/s41375-024-02142.
PubMed Abstract available

KLYUCHNIKOV E, Badbaran A, Massoud R, Freiberger P, et al
Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR.
Leukemia. 2024;38:386-388.
PubMed

ELDEEB M, Konturek-Ciesla A, Zhang Q, Kharazi S, et al
Ontogeny shapes the ability of ETV6::RUNX1 to enhance hematopoietic stem cell self-renewal and disrupt early lymphopoiesis.
Leukemia. 2024;38:455-459.
PubMed

GEORGI JA, Stasik S, Kramer M, Meggendorfer M, et al
Prognostic impact of CEBPA mutational subgroups in adult AML.
Leukemia. 2024;38:281-290.
PubMed Abstract available

HEHLMANN R, Lauseker M
How to individualize therapy after failing milestones in chronic myeloid leukaemia: weighting late response and early death from CML against risk of alternative therapies.
Leukemia. 2024;38:465-466.
PubMed

CHEN J, Gale RP
Response to Pfirrmann et al.'s comment on How should we interpret conclusions of TKI-stopping studies.
Leukemia. 2024;38:463-464.
PubMed

LEE KH, Lee S, Park YH, Mun YC, et al
Interleukin-15 and -21-activated, donor-derived NK cell infusion after haploidentical HCT in high-risk AML and MDS-a cohort analysis.
Leukemia. 2024;38:451-454.
PubMed

MATTANO LA JR, Devidas M, Loh ML, Raetz EA, et al
Development of osteonecrosis and improved survival in B-ALL: results of Children's Oncology Group Trial AALL0232.
Leukemia. 2024;38:258-265.
PubMed Abstract available

CHEN Y, Wen J, Li Q, Peng D, et al
RAB27B-regulated exosomes mediate LSC maintenance via resistance to senescence and crosstalk with the microenvironment.
Leukemia. 2024;38:266-280.
PubMed Abstract available

SUI P, Ge G, Chen S, Bai J, et al
SRSF2 mutation cooperates with ASXL1 truncated alteration to accelerate leukemogenesis.
Leukemia. 2024;38:408-411.
PubMed

January 2024

DAM M, Centanni M, Friberg LE, Centanni D, et al
Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia.
Leukemia. 2024 Jan 29. doi: 10.1038/s41375-024-02153.
PubMed Abstract available

JABBOUR E, Apperley J, Cortes J, Rea D, et al
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
Leukemia. 2024 Jan 29. doi: 10.1038/s41375-024-02159.
PubMed Abstract available

FLYGT H, Soderlund S, Richter J, Saussele S, et al
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
Leukemia. 2024 Jan 26. doi: 10.1038/s41375-024-02145.
PubMed Abstract available

TAN SH, Tan TK, Yokomori R, Liao M, et al
Correction to: TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia.
Leukemia. 2024 Jan 25. doi: 10.1038/s41375-023-02125.
PubMed

TETTERO JM, Heidinga ME, Mocking TR, Fransen G, et al
Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia.
Leukemia. 2024 Jan 25. doi: 10.1038/s41375-024-02158.
PubMed Abstract available

APPELBAUM JS, Wei AH, Mandrekar SJ, Tiong IS, et al
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts.
Leukemia. 2024 Jan 23. doi: 10.1038/s41375-024-02143.
PubMed

KANG H, Hoang DH, Valerio M, Pathak K, et al
OST-01, a natural product from Baccharis coridifolia, targets c-Myc-dependent ribogenesis in acute myeloid leukemia.
Leukemia. 2024 Jan 17. doi: 10.1038/s41375-024-02146.
PubMed

TOMA MM, Karami A, Nieborowska-Skorska M, Chirtala KN, et al
Clonal medicine targeting DNA damage response eradicates leukemia.
Leukemia. 2024 Jan 16. doi: 10.1038/s41375-024-02138.
PubMed

CHEN DW, Fan JM, Schrey JM, Mitchell DV, et al
Inflammatory recruitment of healthy hematopoietic stem and progenitor cells in the acute myeloid leukemia niche.
Leukemia. 2024 Jan 16. doi: 10.1038/s41375-024-02136.
PubMed Abstract available

HANEL G, Schonle A, Neumann AS, Nixdorf D, et al
Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment.
Leukemia. 2024 Jan 11. doi: 10.1038/s41375-023-02127.
PubMed

VALTIS YK, Flamand Y, Shimony S, Place AE, et al
Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols.
Leukemia. 2024 Jan 5. doi: 10.1038/s41375-023-02115.
PubMed Abstract available

SUNG PJ, Selvam M, Riedel SS, Xie HM, et al
FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia.
Leukemia. 2024 Jan 5. doi: 10.1038/s41375-023-02131.
PubMed Abstract available

POTLURI S, Kellaway SG, Coleman DJL, Keane P, et al
Gene regulation in t(6;9) DEK::NUP214 Acute Myeloid Leukemia resembles that of FLT3-ITD/NPM1 Acute Myeloid Leukemia but with an altered HOX/MEIS axis.
Leukemia. 2024 Jan 4. doi: 10.1038/s41375-023-02118.
PubMed

MORLEY AA
Quantifying measurable residual disease correctly.
Leukemia. 2024;38:221-222.
PubMed

TYAGI A, Jaggupilli A, Ly S, Yuan B, et al
TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax.
Leukemia. 2024;38:82-95.
PubMed Abstract available

ZHOU YL, Zhao MY, Gale RP, Jiang H, et al
Mutations in DEAD/H-box helicase 11 correlate with increased relapse risk in adults with acute myeloid leukaemia with normal cytogenetics.
Leukemia. 2024;38:223-225.
PubMed

CHEN J
Response to comment on Have we been qualifying measurable residual disease correctly?
Leukemia. 2024;38:219-220.
PubMed

RADIVOYEVITCH T, Gale RP, Kalaycio ME
What do atomic bomb survivors teach us about therapy-free remission in people with chronic myeloid leukaemia?
Leukemia. 2024;38:207-209.
PubMed

GARCIA-MANERO G, Podoltsev NA, Othus M, Pagel JM, et al
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.
Leukemia. 2024;38:58-66.
PubMed Abstract available

YAN M, Liu M, Davis AG, Stoner SA, et al
Single-cell RNA sequencing of a new transgenic t(8;21) preleukemia mouse model reveals regulatory networks promoting leukemic transformation.
Leukemia. 2024;38:31-44.
PubMed Abstract available

December 2023

AKIYAMA H, Zhao R, Ostermann LB, Li Z, et al
Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia.
Leukemia. 2023 Dec 26. doi: 10.1038/s41375-023-02117.
PubMed Abstract available

YANADA M, Yamasaki S, Kondo T, Kawata T, et al
Allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia not in remission.
Leukemia. 2023 Dec 21. doi: 10.1038/s41375-023-02119.
PubMed Abstract available

MACHOVA POLAKOVA K, Albeer A, Polivkova V, Krutska M, et al
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib.
Leukemia. 2023 Dec 21. doi: 10.1038/s41375-023-02109.
PubMed Abstract available

DE SMITH AJ, Wiemels JL, Mead AJ, Roberts I, et al
Backtracking to the future: unraveling the origins of childhood leukemia.
Leukemia. 2023 Dec 20. doi: 10.1038/s41375-023-02111.
PubMed

FIJALKOWSKI I, Wang J, Jin Q, Van Laere J, et al
Correction: A positive feedback loop regulation between NOTCH1 and USP11 in T-cell leukemia.
Leukemia. 2023 Dec 19. doi: 10.1038/s41375-023-02112.
PubMed

MURPHY T, Mason JM, Leber B, Bray MR, et al
Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms.
Leukemia. 2023 Dec 19. doi: 10.1038/s41375-023-02110.
PubMed Abstract available

HOFFMEISTER LM, Suttorp J, Walter C, Antoniou E, et al
Panel-based RNA fusion sequencing improves diagnostics of pediatric acute myeloid leukemia.
Leukemia. 2023 Dec 12. doi: 10.1038/s41375-023-02102.
PubMed Abstract available

KOVTUN I, von Bonin M, Ibneeva L, Frimmel J, et al
Profound sympathetic neuropathy in the bone marrow of patients with acute myeloid leukemia.
Leukemia. 2023 Dec 8. doi: 10.1038/s41375-023-02104.
PubMed

TANNOURY M, Ayoub M, Dehgane L, Nemazanyy I, et al
ACOX1-mediated peroxisomal fatty acid oxidation contributes to metabolic reprogramming and survival in chronic lymphocytic leukemia.
Leukemia. 2023 Dec 6. doi: 10.1038/s41375-023-02103.
PubMed Abstract available

SABA L, Landau KS, Liang H, Fu CL, et al
Real world analysis on the determinants of survival in primary plasma cell leukemia in the United States.
Leukemia. 2023 Dec 4. doi: 10.1038/s41375-023-02100.
PubMed

ANTIC Z, van Bommel A, Riege K, Lentes J, et al
Recurrent DNMT3B rearrangements are associated with unfavorable outcome in dicentric (9;20)-positive pediatric BCP-ALL.
Leukemia. 2023;37:2522-2525.
PubMed

SCHIFFER CA
Glasdigib fails to slay the hedgehog in pivotal AML trials.
Leukemia. 2023;37:2520-2521.
PubMed

BOUCHLA A, Papageorgiou SG, Symeonidis A, Sakellari I, et al
Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients' outcome?
Leukemia. 2023;37:2517-2519.
PubMed

XIANG J, Devenport JM, Carter AJ, Staser KW, et al
An "off-the-shelf" CD2 universal CAR-T therapy for T-cell malignancies.
Leukemia. 2023;37:2448-2456.
PubMed Abstract available

November 2023

MILIARA S, Cozzi E, Zhong X, Chan I, et al
The exon-junction complex helicase eIF4A3 holds therapeutic potential in acute myeloid leukemia.
Leukemia. 2023 Nov 30. doi: 10.1038/s41375-023-02098.
PubMed

PLAYA-ALBINYANA H, Arenas F, Royo R, Giro A, et al
Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation.
Leukemia. 2023 Nov 28. doi: 10.1038/s41375-023-02095.
PubMed Abstract available

OZGA M, Nicolet D, Mrozek K, Yilmaz AS, et al
Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).
Leukemia. 2023 Nov 28. doi: 10.1038/s41375-023-02068.
PubMed Abstract available

ROSTI G, Brummendorf TH, Gjertsen BT, Giraldo-Castellano P, et al
Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study.
Leukemia. 2023 Nov 25. doi: 10.1038/s41375-023-02080.
PubMed Abstract available

FIJALKOWSKI I, Wang J, Jin Q, Van Laere J, et al
A positive feedback loop regulation between NOTCH1 and USP11 in T-cell leukemia.
Leukemia. 2023 Nov 25. doi: 10.1038/s41375-023-02096.
PubMed

LEUNG KT, Cai J, Liu Y, Chan KYY, et al
Prognostic implications of CD9 in childhood acute lymphoblastic leukemia: insights from a nationwide multicenter study in China.
Leukemia. 2023 Nov 25. doi: 10.1038/s41375-023-02089.
PubMed Abstract available

ZALIOVA M, Zuna J, Winkowska L, Janotova I, et al
Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study.
Leukemia. 2023 Nov 24. doi: 10.1038/s41375-023-02083.
PubMed Abstract available

WALTER RB
Perspective on measurable residual disease testing in acute myeloid leukemia.
Leukemia. 2023 Nov 16. doi: 10.1038/s41375-023-02084.
PubMed

WU Y, Zehnle PMA, Rajak J, Koleci N, et al
BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia.
Leukemia. 2023 Nov 9. doi: 10.1038/s41375-023-02079.
PubMed Abstract available

ALSHAMLEH I, Kurrle N, Makowka P, Bhayadia R, et al
PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia.
Leukemia. 2023 Nov 7. doi: 10.1038/s41375-023-02041.
PubMed Abstract available

TOMIZAWA D, Matsubayashi J, Iwamoto S, Hiramatsu H, et al
High-dose cytarabine induction therapy and flow cytometric measurable residual disease monitoring for children with acute myeloid leukemia.
Leukemia. 2023 Nov 6. doi: 10.1038/s41375-023-02075.
PubMed

HUUHTANEN J, Adnan-Awad S, Theodoropoulos J, Forsten S, et al
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation.
Leukemia. 2023 Nov 2. doi: 10.1038/s41375-023-02074.
PubMed Abstract available

WEISCHENDORFF S, Rathe M, Petersen MJ, Weimann A, et al
Markers of intestinal mucositis to predict blood stream infections at the onset of fever during treatment for childhood acute leukemia.
Leukemia. 2023 Nov 2. doi: 10.1038/s41375-023-02077.
PubMed Abstract available

FALINI B, Gjertsen BT, Andresen V
The acidic stretch and the C-terminal nuclear export signal motif of NPM1 mutant: are they druggable in AML?
Leukemia. 2023;37:2173-2175.
PubMed

LAUSEKER M, Hehlmann R, Hochhaus A, Saussele S, et al
Survival with chronic myeloid leukaemia after failing milestones.
Leukemia. 2023;37:2231-2236.
PubMed Abstract available

DU W, Xia Z, Luo Z, Chen Y, et al
A novel gene fusion RUNX1/ZNF423 promotes leukemic relapse of NUP98-rearranged AML.
Leukemia. 2023;37:2286-2291.
PubMed

BUROCZIOVA M, Danek P, Oravetzova A, Chalupova Z, et al
Ppm1d truncating mutations promote the development of genotoxic stress-induced AML.
Leukemia. 2023;37:2209-2220.
PubMed Abstract available

FENG Y, Qi S, Liu X, Zhang L, et al
Have we been qualifying measurable residual disease correctly?
Leukemia. 2023;37:2168-2172.
PubMed

LI S, Wang X, Liu L, Liu J, et al
CD7 targeted "off-the-shelf" CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies.
Leukemia. 2023;37:2176-2186.
PubMed Abstract available

October 2023

CERELLA C, Gajulapalli SR, Lorant A, Gerard D, et al
ATP1A1/BCL2L1 predicts the response of myelomonocytic and monocytic acute myeloid leukemia to cardiac glycosides.
Leukemia. 2023 Oct 30. doi: 10.1038/s41375-023-02076.
PubMed Abstract available

BISCHOF L, Ussmann J, Grimm J, Bill M, et al
Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation.
Leukemia. 2023 Oct 25. doi: 10.1038/s41375-023-02072.
PubMed

V STACKELBERG A, Jaschke K, Jousseaume E, Templin C, et al
Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Leukemia. 2023 Oct 25. doi: 10.1038/s41375-023-02042.
PubMed Abstract available

WU A, Yen R, Grasedieck S, Lin H, et al
Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis.
Leukemia. 2023 Oct 17. doi: 10.1038/s41375-023-02062.
PubMed Abstract available

JOHANSSON KB, Zimmerman MS, Dmytrenko IV, Gao F, et al
Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia.
Leukemia. 2023 Oct 14. doi: 10.1038/s41375-023-02057.
PubMed Abstract available

DEL GIUDICE I, Foa R
Measurable residual disease in chronic lymphocytic leukemia. Where do we stand?
Leukemia. 2023 Oct 14. doi: 10.1038/s41375-023-02066.
PubMed

ECKARDT JN, Stasik S, Rollig C, Petzold A, et al
Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia.
Leukemia. 2023 Oct 13. doi: 10.1038/s41375-023-02061.
PubMed Abstract available

OTTONE T, Silvestrini G, Piazza R, Travaglini S, et al
Expression profiling of extramedullary acute myeloid leukemia suggests involvement of epithelial-mesenchymal transition pathways.
Leukemia. 2023 Oct 6. doi: 10.1038/s41375-023-02054.
PubMed Abstract available

KANTARJIAN HM
What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia.
Leukemia. 2023 Oct 5. doi: 10.1038/s41375-023-02053.
PubMed

TULKENS D, Boelens M, Naert T, Carron M, et al
Mutations in the histone methyltransferase Ezh2 drive context-dependent leukemia in Xenopus tropicalis.
Leukemia. 2023 Oct 4. doi: 10.1038/s41375-023-02052.
PubMed Abstract available

CROSS NCP, Ernst T, Branford S, Cayuela JM, et al
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia.
Leukemia. 2023 Oct 4. doi: 10.1038/s41375-023-02048.
PubMed Abstract available

JAHN E, Saadati M, Fenaux P, Gobbi M, et al
Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients.
Leukemia. 2023 Oct 3. doi: 10.1038/s41375-023-02017.
PubMed

HUBER S, Baer C, Hutter S, Dicker F, et al
Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC.
Leukemia. 2023;37:2138-2141.
PubMed

OTHMAN J, Potter N, Mokretar K, Taussig D, et al
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML.
Leukemia. 2023;37:2066-2072.
PubMed Abstract available

FISHER JG, Doyle ADP, Graham LV, Sonar S, et al
XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression.
Leukemia. 2023;37:2036-2049.
PubMed Abstract available

CASERTA C, Nucera S, Barcella M, Fazio G, et al
miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease.
Leukemia. 2023;37:1994-2005.
PubMed Abstract available

TIAN Z, Shi C, Yang G, Allen JK, et al
Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL.
Leukemia. 2023;37:2006-2016.
PubMed Abstract available

GURULE NJ, Malcolm KC, Harris C, Knapp JR, et al
Myelodysplastic neoplasm-associated U2AF1 mutations induce host defense defects by compromising neutrophil chemotaxis.
Leukemia. 2023;37:2115-2124.
PubMed Abstract available

September 2023

MALIK N, Hay J, Almuhanna HNB, Dunn KM, et al
mTORC1-selective activation of translation elongation promotes disease progression in chronic lymphocytic leukemia.
Leukemia. 2023 Sep 29. doi: 10.1038/s41375-023-02043.
PubMed Abstract available

JONDREVILLE L, Dehgane L, Doualle C, Smagghe L, et al
del(8p) and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia.
Leukemia. 2023 Sep 26. doi: 10.1038/s41375-023-02035.
PubMed Abstract available

FECHINA L, Popov A, Tsaur G, Henze G, et al
Combination of chemotherapy and all-trans retinoic acid for the treatment KMT2A-rearranged infant acute lymphoblastic leukemia. Results of the MLL-Baby trial.
Leukemia. 2023 Sep 23. doi: 10.1038/s41375-023-02034.
PubMed

KUBASCH AS, Peterlin P, Cluzeau T, Gotze KS, et al
Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial.
Leukemia. 2023 Sep 21. doi: 10.1038/s41375-023-02029.
PubMed

DOBISH KK, Wittorf KJ, Swenson SA, Bean DC, et al
FBXO21 mediated degradation of p85alpha regulates proliferation and survival of acute myeloid leukemia.
Leukemia. 2023 Sep 9. doi: 10.1038/s41375-023-02020.
PubMed Abstract available

ECKARDT JN, Bill M, Rausch C, Metzeler K, et al
Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European leukemia net risk classification.
Leukemia. 2023 Sep 7. doi: 10.1038/s41375-023-02016.
PubMed

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum